Godavari Biorefineries Limited

Conference Call Details

• Event: Earnings Conference Call for Q2 and H1 FY27
• Date: Friday, November 6, 2026
• Time: 11:00 AM IST

Management Participants

• Mr. Samir Somaiya: Chairman & Managing Director
• Mr. Ashish Sinha: DGM, Investor Relations & Finance

This filing is a routine notification of the company's scheduled investor conference call to discuss financial and operational performance for the quarter and half-year ended September 30, 2026.

Key Highlights

Trading Window Closure

In accordance with the company's 'Insider Trading Code' and SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities is closed for all Directors, Key Managerial Personnel, Designated Persons, and their immediate relatives. This closure period commenced on October 1, 2026, and will continue until 48 hours after the declaration of the unaudited financial results.

Publication Details

Godavari Biorefineries Limited has complied with SEBI Listing Regulations (LODR) by publishing a notice in the Financial Express (English) and Mumbai Lakshdeep (Marathi) on October 17, 2026. The notice formally informs shareholders of a "Special Window for Re-lodgement of Transfer Request of Physical Shares."

Notice Purpose

The publication serves to notify shareholders who may have submitted physical share transfer requests prior to April 1, 2019, which were subsequently rejected, returned, or remained unaddressed due to various procedural reasons.

Important Dates

• Special Window Period: February 5, 2026, to February 4, 2027.
• Newspaper Publication Date: October 17, 2026.

Shareholder Instructions

Eligible shareholders are advised to coordinate with the company's Registrar and Transfer Agent (RTA). All re-lodgement requests must be processed via the dematerialization mode.

Contact Details:

• Registrar and Transfer Agent: M/s Bigshare Services Private Limited.
• Email: rnt.helpdesk@in.mpms.mufg.com
• Contact Number: 1800 1020 878

Regulatory Context

This initiative is conducted in accordance with SEBI Circular No. HO/38/13/11(2)/2026-MIRSD-POD/I/3750/2026, dated January 30, 2026.

What Shareholders Should Know

This is an administrative procedural notice. Existing shareholders holding physical shares that were previously rejected or returned may utilize this designated window to rectify and re-lodge their transfer requests.

Patent Grant Announcement

Godavari Biorefineries Ltd has informed the stock exchanges that the United States Patent and Trademark Office (USPTO) has granted a patent for a compound developed by the company.

Patent Details

• Patent Title: 5-Hydroxy-1,4-Naphthalenedione for use in the treatment of cancer
• Status: Granted
• Scope: The patent protects a novel class of compounds that target and effectively inhibit cancer and cancer stem cells.
• Application: The company stated that the compounds show significant potential against various cancer types, including breast and prostate cancers.

What This Means for Investors

The receipt of a patent in the US market represents a significant intangible asset for the company. It provides the firm with exclusive rights to the protected compounds, which may enhance its valuation and future development pipeline. While the company has not disclosed the immediate commercialization timelines or projected financial impact of this specific patent, the development serves as a tangible indicator of the success and progress of the company's research and development initiatives. Shareholders should monitor any subsequent announcements regarding potential partnerships, licensing agreements, or clinical progress related to this intellectual property.

Regulatory Compliance Update

Godavari Biorefineries Ltd has filed a compliance certificate as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September 2026.

The certificate was issued by MUFG Intime India Private Ltd, the company's Registrar and Share Transfer Agent (RTA). It confirms the following actions taken during the quarter:

• Processing of Securities: Securities received from depository participants for dematerialization were processed, with confirmations (accepted/rejected) communicated to the depositories.
• Verification and Cancellation: Security certificates received for dematerialization were verified, mutilated, and cancelled.
• Regulatory Compliance: The names of the depositories have been successfully substituted in the register of members as the registered owner within the timelines prescribed by SEBI.

This filing is a routine procedural requirement to ensure transparency and compliance with depository and participant regulations.

Publication Details The company, Godavari Biorefineries Ltd, submitted a notice regarding a newspaper publication in compliance with Regulation 30 and 47 of the SEBI (LODR) Regulations, 2015. The circular was published in the Financial Express (English) and Mumbai Lakshdeep (Marathi) on 3rd October, 2026. ## Regulatory Context The advertisement functions as a circular inviting public deposits under the relevant regulatory framework, ensuring transparent disclosure to shareholders and potential depositors. ## What Shareholders Should Know This is a standard statutory publication confirming the company's adherence to regulatory disclosure norms concerning public deposits. Investors are advised to view the notice as part of routine compliance reporting.

Patent Grant Update

Godavari Biorefineries Ltd has received a formal patent grant from the Mexican Patent Office. The disclosure, filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirms the protection of new intellectual property in the international market.

Patent Specifications

The invention focuses on the use of compounds that inhibit V-ATPase activity in cells. The patent covers the application of these compounds in the manufacture of medicaments intended for the treatment of viral infections.

Significance for Investors

For shareholders, this patent grant represents the successful validation of the company's research efforts in the biotechnology and pharmaceutical space. While intellectual property grants strengthen the company's competitive position and long-term research portfolio, they do not have an immediate or guaranteed impact on current revenue streams or profitability. The primary value lies in the future potential to commercialize the licensed technology or utilize it in collaborative ventures.

Investor Takeaway

The granting of this patent is a positive development for the company's R&D credibility. Investors should monitor future updates regarding the practical application, potential licensing, or development status of the technology covered by this patent to assess its long-term commercial impact.

Key Highlights

Godavari Biorefineries Ltd (Scrip Code: 544279) successfully conducted its 71st Annual General Meeting (AGM) on September 28, 2026. Shareholders voted on 10 resolutions, all of which were passed with the support of the promoter group.

Voting Overview

Institutional Dissent Analysis

While all resolutions passed, data from the consolidated scrutinizer's report reveals significant opposition from 'Public Institutions' on three specific resolutions. The promoter group, holding 32,400,110 shares, voted in favor of all resolutions, effectively neutralizing the institutional dissent.

Notable Institutional Opposition

• Resolution 4 (MD Remuneration): Institutional investors voted 52.52% against the proposal to approve the terms of re-appointment and remuneration for Managing Director Mr. Samir S. Somaiya (effective April 1, 2027).
• Resolution 9 (Charitable Contributions): Institutional investors voted 48.50% against the proposal to contribute to charitable and other funds.
• Resolution 10 (Acceptance of Deposits): Institutional investors voted 48.50% against the proposal to approve the acceptance of deposits.

Management and Governance Update

• Managing Director: The re-appointment and remuneration terms for Mr. Samir S. Somaiya as MD were approved (w.e.f. April 1, 2027).
• Executive Directors: The appointment and remuneration terms for Mr. Suhas Godage (Works-Sakarwadi) and Mr. Dinesh Sharma (Works-Sameerwadi) were approved.
• Director Appointments: Mr. Dinesh Sharma was appointed as a Director of the Company.

Investor Takeaway

While the company successfully cleared its AGM agenda, the voting pattern highlights a divide between institutional shareholders and promoters regarding specific governance and financial policies. The dissent on the Managing Director's remuneration terms and deposit acceptance policies warrants continued monitoring by existing shareholders to gauge potential future friction between management and institutional capital.

Board and Management Update

Godavari Biorefineries Ltd has announced the outcome of its 71st Annual General Meeting held on September 28, 2026, where shareholders approved several board changes.

Key Appointments and Re-appointments

• Dr. Raman Ramchandran: Re-appointed as Director, liable to retire by rotation.
• Mr. Suhas Godage: Re-appointed as Director, liable to retire by rotation.
• Mr. Samir S. Somaiya: Re-appointed as Managing Director effective April 1, 2027.
• Mr. Suhas Godage: Re-appointed as Executive Director (Works-Sakarwadi) effective April 1, 2027.
• Mr. Dinesh Sharma: Appointed as a Director of the Company. Additionally, he was appointed as Executive Director (Works-Sameerwadi) for a three-year term.

All directors have confirmed that they are not debarred from holding the office of director by virtue of any SEBI order or any other authority.

AGM Summary

Godavari Biorefineries Ltd convened its 71st Annual General Meeting (AGM) on September 28, 2026, conducted through Video Conferencing (VC) and Other Audio-Visual Means (OAVM). The meeting commenced at 11:30 a.m. and concluded at 11:49 a.m.

Key Agenda Items

The company presented ten items for shareholder consideration in the Notice dated August 5, 2026:

Ordinary Business:

• Financial Adoption: Consideration and adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026.
• Director Appointments: Appointment of Dr. Raman Ramchandran and Mr. Suhas Godage, both directors retiring by rotation.

Special Business:

• Leadership Re-appointments:
  • Approval of re-appointment and remuneration of Mr. Samir S. Somaiya as Managing Director, effective April 1, 2027.
  • Approval of re-appointment and remuneration of Mr. Suhas Godage as Executive Director (Works-Sakarwadi), effective April 1, 2027.
• Director Appointment:
  • Appointment of Mr. Dinesh Sharma as a Director.
  • Approval of the terms of appointment and remuneration of Mr. Dinesh Sharma as a whole-time director designated as Executive Director (Works-Sameerwadi) for three years.
• Other Matters: Ratification of remuneration for the Cost Auditor, contribution to charitable and other funds, and acceptance of deposits.

Voting and Proceedings

• Participation: 91 members attended the meeting via VC/OAVM.
• Voting Process: The company provided a remote e-voting facility from September 25, 2026, to September 27, 2026. An electronic voting system was also available for members during the meeting.
• Scrutinizer: Mr. Tushar Shridharani of Tushar Shridharani and Associates LLP was appointed as the scrutinizer to oversee the voting process.
• Results: The combined voting results are to be intimated to the Stock Exchanges and uploaded on the websites of the company and NSDL.

Trading Window Closure

Godavari Biorefineries Ltd has formally intimated the stock exchanges regarding the closure of its trading window for dealing in the company's securities. This measure is in accordance with the company's "Insider Trading Prohibition Code" and the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Scope and Timing

• Effective Date: The trading window closure commences on October 1, 2026.
• Applicability: The restriction applies to all Directors, Key Managerial Persons (KMP), designated persons, and their immediate relatives or dependents.
• Duration: The trading window will remain closed until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ended September 30, 2026.

Next Steps

The company has stated that the specific date of the board meeting to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026, will be communicated in due course.

Meeting Intimation

Godavari Biorefineries Ltd has informed the stock exchanges regarding its participation in an upcoming investor and analyst interaction scheduled for September 29, 2026.

Event Details

• Event Name: Bharat Connect-Arihant Capital Virtual Conference
• Date: September 29, 2026
• Format: Virtual Group Meeting

Management Disclosure

The company has clarified that the discussions during this meeting will be based solely on publicly available information. No unpublished price-sensitive information (UPSI) is proposed to be shared or discussed during the event.

Patent Grant Overview

Godavari Biorefineries Ltd has informed the stock exchanges that it has received a patent grant from the Chinese Patent Office. The grant, dated September 15, 2026, covers the company's application regarding the treatment of viral infections.

Invention Details

The granted patent (Patent No. ZL 2021 8 0048053.9; Grant Publication No. CN 115867276 B) is titled "Use of Compounds for Treating Viral Infections."

According to the disclosure, the invention relates to:

• The use of specific compounds for inhibiting V-ATPase activity in cells.
• The application of these compounds in the manufacture of medicaments intended for the treatment of viral infections.

Investor Takeaway

This development strengthens the company’s intellectual property portfolio in the biotechnology and pharmaceutical space. However, it is important for investors to note that a patent grant is a precursor to potential commercialization, not an indicator of immediate revenue or profit generation. The company has not disclosed any specific plans for product development, clinical trials, or partnerships related to this patent. As such, while it validates the company's research focus, it remains a long-term R&D metric rather than a short-term financial driver.

Patent Grant Details

Godavari Biorefineries Ltd has formally announced that the European Patent Office (EPO) has granted a patent for its invention, titled "A Biofiller for Rubber Reinforcement." The grant certificate, dated August 12, 2026, assigns patent number EP3313916 to the company.

Technology Significance

The patented technology represents a bio-based solution designed to partially replace conventional carbon black used in rubber reinforcement. Key aspects of the invention include:

• Sustainability: The biofiller is described as biodegradable and eco-friendly.
• Functionality: It is designed to maintain or improve the key mechanical properties of rubber products.
• Scalability: The company claims the invention offers a scalable manufacturing process.
• Applications: The biofiller is intended for use in products such as tyres, footwear, belts, bags, and other industrial rubber goods.

Investor Implications

For shareholders, the granting of this patent is a positive development that strengthens the company’s intellectual property (IP) portfolio. The move supports the company's strategic focus on sustainable materials and may open avenues for future commercialization, given that it addresses the performance-cost-environmental balance required in the rubber manufacturing industry.

Investor Takeaway

This announcement confirms a successful R&D milestone for the company in the sustainable chemicals space. While the patent grant is an important indicator of technical viability, investors should monitor for future updates regarding the commercialization timeline, potential partnerships with rubber manufacturers, and the company's progress in scaling the production of this biofiller.

Publication Details

Godavari Biorefineries Ltd published the notice for its 71st Annual General Meeting (AGM) and e-voting instructions in the Financial Express and Mumbai Lakshyadep newspapers on September 5, 2026.

Important Dates

Shareholder Instructions

• Meeting Attendance: The AGM will be conducted exclusively via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). No physical presence is required.
• Remote E-voting: Eligible shareholders may cast their votes electronically through the e-voting platform provided by the company, starting September 25, 2026.
• Eligibility: Shareholders holding shares as of the cut-off date, September 21, 2026, are entitled to participate and vote on the resolutions.
• Access: The annual report and AGM notice are available on the company's official website and the designated depository website.

Regulatory Context

The publication adheres to the Companies Act, 2013, read with the Companies (Management and Administration) Rules, 2014, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The proceedings are in accordance with the circulars issued by the Ministry of Corporate Affairs and SEBI regarding the conduct of AGMs through VC/OAVM.

Financial Performance Summary

Godavari Biorefineries Ltd returned to profitability in FY 2025-26. On a standalone basis, the company reported a Profit After Tax (PAT) of Rs 1.24 crore (Rs 123.62 lakh), compared to a loss of Rs 27.16 crore (Rs 2,715.97 lakh) in FY 2024-25. Consolidated revenue grew by 6.29% to Rs 1,987.94 crore (Rs 1,98,794.26 lakh).

Important Figures (Standalone, Rs in Crore)

Business and Operational Highlights

• Sugar & Co-generation: The company reported a sugarcane crush of 24.6 lakh tonnes. Sugar revenue stood at Rs 688.74 crore (Rs 68,873.62 lakh) on a standalone basis.
• Ethanol: The company commissioned a 200,000 lpd ethanol facility using maize/grain, allowing for multi-feedstock flexibility.
• Bio-based Chemicals: Revenue from this segment was Rs 575.57 crore (Rs 57,557.09 lakh) standalone. The bio-based specialty chemicals contribution to total bio-based chemicals revenue increased to 61% from 58% in the previous year.
• Consumer Brand ('Jivana'): The Jivana business achieved revenues exceeding Rs 129 crore in 2025-26.

Strategic Developments

• Technology Licensing: Signed an agreement with Catalyxx for Bio-Butanol production (30,000 tonnes capacity targeted).
• R&D: Progressing on drug discovery for triple-negative breast cancer (TNBC), with trials expected to commence in Q3 FY27.
• Sustainability: The company maintains a Zero Liquid Discharge (ZLD) facility and utilizes biomass for renewable energy generation.

Management Commentary

Management emphasized the success of their integrated biorefinery model and the benefit of diversifying the feedstock base (sugarcane and grain). Prudent financial management led to lower finance costs during the year, supporting the company's return to profitability. The company remains focused on enhancing product mix and operational efficiency.

Concerns and Watch Points

• Regulatory Risks: The company is managing ongoing disputes related to cross-subsidy surcharges, ethanol pricing, and customs duty issues, though management noted positive developments in the NGT case regarding environmental allegations.
• Market Uncertainties: Global geopolitical conflicts and inflation remain key external risk factors influencing commodity prices and supply chain stability.

Investor Takeaway

The company’s return to profitability and the successful diversification of its feedstock base are key positive developments. Investors should continue to monitor the progress of the TNBC drug discovery trials and the company's success in managing regulatory and legal disputes.

71st Annual General Meeting Details

Godavari Biorefineries Ltd has scheduled its 71st Annual General Meeting (AGM) for Monday, 28th September 2026, at 11:30 AM (IST). The meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM) in accordance with the relevant regulatory frameworks.

Annual Report Availability

In compliance with Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company is dispatching a letter to members who have not registered their email addresses with the company, their Depository Participant, or the Registrar and Share Transfer Agent (RTA). This communication provides access to the company's Annual Report for the financial year 2025-26, which is available on the company's official website.

KYC Compliance Reminder

The company has issued a reminder for shareholders holding securities in physical mode to update their KYC records. In line with SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37, security holders are required to register the following information:

• Permanent Account Number (PAN)
• Address with PIN code
• Mobile Number
• Bank Account details
• Specimen Signature
• Choice of Nomination

The company emphasized that as of April 1, 2024, payments such as dividends, interest, or redemptions for folios without updated PAN, nomination, contact, bank, and signature details are only permitted through electronic mode. Shareholders are encouraged to register their email IDs to facilitate digital communication and electronic service delivery.

Key Highlights

Important Figures (Standalone, FY26)

Management and Governance Update

The company has proposed the following board appointments and reappointments for shareholder approval:

• Mr. Samir S. Somaiya: Re-appointment as Managing Director for 3 years (w.e.f. 1st April 2027 to 31st March 2030).
• Mr. Suhas Godage: Re-appointment as Whole-time Director (Executive Director - Works, Sakarwadi) for 3 years (w.e.f. 1st April 2027 to 31st March 2030).
• Mr. Dinesh Sharma: Appointment as Whole-time Director (Executive Director - Works, Sameerwadi) for 3 years (w.e.f. the date of the AGM).

Business and Operational Updates

• Expansion Plans: The company's Sameerwadi facility currently has a sugarcane crushing capacity of 20,000 TCD (expandable to 25,000 TCD) and an ethanol production capacity of 570 KLPD (planned scale-up to 1,000 KLPD).
• Operational Challenges: Management noted that FY2025-26 was a challenging year for the sugar and ethanol industries, citing elevated cane and feedstock costs. The ethanol segment faced a compressed margin environment due to pricing dynamics and feedstock economics.
• Fixed Deposits: The company seeks member approval to invite/accept/renew fixed deposits from the public and members to augment working capital and provide an investment platform to employees.
• Charitable Contribution: Approval is sought to contribute up to Rs 1.40 crore to charitable institutions and funds in a financial year.

Investor Takeaway

This AGM serves as a standard governance exercise for Godavari Biorefineries. Shareholders should note the management's focus on capacity optimization and scaling the ethanol business, despite the margin pressures experienced in FY26 due to raw material costs. The proposed reappointments ensure leadership continuity.

Legal, Tax, or Regulatory Update

Godavari Biorefineries Ltd has announced that it received a show-cause notice from the Office of the Commercial Tax Officer (Enforcement), DGSTO, Jamkhandi, Karnataka. The notice, issued under sub-section (1) of Section 73 of the CGST/KGST Act, 2017, relates to allegations of short payment, non-payment, or the availment of ineligible input tax credit for the tax period 2022-23.

Demand Breakdown

The total GST demand, including interest and penalty, aggregates to approximately Rs 18.13 crore. The following table summarizes the financial components of the notice:

Note: The base tax demand of Rs 10.57 crore comprises IGST (Rs 5.13 crore), CGST (Rs 2.69 crore), SGST (Rs 2.69 crore), and CESS (Rs 0.06 crore).

Management Response

The company stated that it is currently evaluating the notice to assess its potential material impact on financial, operational, and other activities. The management has confirmed that it is in the process of reviewing the documentation and intends to take necessary legal steps, which may include filing formal replies or appeals as advised by its legal counsel.

What This Means for Investors

For existing shareholders, the primary concern is the potential financial outflow and the uncertainty surrounding the litigation process. While the company is contesting or evaluating the matter, this development requires monitoring, particularly regarding how it might affect the company's cash position or tax provisions in future periods. Investors should watch for further updates on whether the company opts to settle the claim or pursue a legal challenge, as this will determine the timeline and final financial impact.

Publication Details

Godavari Biorefineries Ltd has announced the scheduling of its 71st Annual General Meeting (AGM). The notice confirms the meeting will occur on Monday, September 28, 2026, at 11:30 AM (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM), as permitted by the Ministry of Corporate Affairs and SEBI.

Important Dates

Shareholder Instructions

The company emphasizes that shareholders who have not yet registered their email addresses are required to do so to receive the Annual Report and the AGM notice.

• For Physical Shareholding: Shareholders should email the registrar, Link Intime India Pvt Ltd, at rnt.helpdesk@in.mpms.mufg.com with their folio number, name, self-attested PAN, and Aadhaar card copies.
• For Demat Shareholding: Shareholders must update their email ID with their respective Depository Participant (DP) or provide the necessary details (DPID-Client ID, Client Master, PAN, Aadhaar) to the registrar or DP.

Regulatory Context

This notice is issued in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and various circulars issued by the Ministry of Corporate Affairs regarding the conduct of virtual meetings.

What Shareholders Should Know

Shareholders will only be able to attend and participate in the AGM through the virtual mode. The attendance of members through the VC/OAVM facility will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013. Further details regarding the voting process and meeting credentials will be provided in the formal AGM notice dispatched to the members.

Regulatory Notice Overview

Godavari Biorefineries Ltd has informed the stock exchanges that it received a show cause notice (SCN) from the Office of the Assistant Commissioner of Central GST, Audit, Belgavi, Karnataka, on August 21, 2026. The notice relates to the alleged non-payment of GST on the supply of Extra Neutral Alcohol (ENA) to the Karnataka State Beverages Corporation Ltd (KSBCL).

Dispute Details

The dispute centers on the tax treatment of ENA supplied by the company to KSBCL for the manufacturing of alcoholic liquor intended for human consumption. The company had classified these supplies as "exempted supplies" in its GST returns and accordingly did not pay GST on these transactions. The tax authorities have questioned this classification under Section 74(1) of the CGST/SGST Act, 2017.

Financial Implications

The GST authorities have raised a total demand of approximately Rs 17.02 crore, split equally between CGST and SGST.

Management Response and Next Steps

Management stated that they are currently evaluating the material impact of the notice on the company's financial, operational, and other activities. The company plans to take appropriate legal steps, which will include filing replies or appeals as advised by its legal representatives.

Investor Takeaway

For existing shareholders, the key watch point is the outcome of the legal defense against this tax demand. While the company is in the early stages of evaluating the notice, the development introduces a financial liability exposure that will need to be monitored until a resolution is reached or a formal provision is made.

Publication Details

Godavari Biorefineries Limited has published a notice in Financial Express (English) and Mumbai Lakshdeep (Marathi) on August 20, 2026, regarding shareholder services.

Purpose of Notice

Pursuant to the SEBI Circular No. HO/38/13/11(2)/2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, the company has announced a "Special Window for Re-lodgement of Transfer Request of Physical Shares."

This window is provided for shareholders who had lodged physical share transfer requests before April 1, 2019, which were subsequently rejected, not processed, or not returned to the shareholder.

Important Dates

• Window Period: February 5, 2026, to February 4, 2027.

Shareholder Instructions

• Processing Mode: All successfully corrected and re-lodged transfers will be processed in dematerialized (demat) mode only.
• Contact Registrar: Shareholders wishing to avail of this opportunity should contact the company's Registrar and Share Transfer Agent, MUFG Intime India Pvt. Ltd (formerly Link Intime India Pvt. Ltd).
• Contact Details:
  • Email: rnt.helpdesk@in.mpms.mufg.com
  • Phone: 1800 1020 878
  • Address: Unit: Godavari, C-101, Embassy 247, LBS Marg, Vikhroli (West), Mumbai - 400083.

The detailed notice is available on the company website at www.godavaribiorefineries.com.

Key Highlights

Financial Snapshot (Consolidated)

*Calculated implied Q1 FY26 base from 4.9% growth figure.

Segment Performance

Bio-based Chemicals

The chemical business delivered strong performance, benefitting from prior debottlenecking initiatives and a favorable product mix.

• Revenue: Rs 168.7 crore (up 19.4% YoY).
• EBITDA: Rs 19.2 crore (up 53% YoY).
• EBITDA Margin: 11.4% (vs 8.9% in Q1 FY26).

Integrated Sugar, Cogeneration, and Ethanol

The segment remained under pressure due to challenging feedstock conditions and higher manufacturing costs.

• Revenue: Rs 377.9 crore (vs Rs 382.8 crore in Q1 FY26).
• EBITDA Loss: Rs 14.6 crore (vs loss of Rs 4.5 crore in Q1 FY26).

Strategic and Operational Updates

• Capacity Expansion: Management commissioned a 200 KLPD grain-based distillery at Sameerwadi. They are evaluating adding a 160 KLPD fungible capacity (maize/grain preparation) to optimize utilization between sugar and ethanol production.
• Bio-based Chemicals Growth: The company plans to invest Rs 25 crore in debottlenecking to meet growing demand. Management projects this could push quarterly revenue for this segment to approximately Rs 240 crore by early FY28.
• Innovation/R&D: Secured a Japanese patent for an anticancer molecule. The company has filed for CDSCO approval to initiate preliminary efficacy trials, expected to commence by Q3 FY27. R&D spend is estimated at ~Rs 20 crore over 2-3 years.

Management Q&A Highlights

What Looks Positive

• Chemical Segment Momentum: The segment is showing strong operational leverage with significant margin expansion (to 11.4%).
• Strategic Optionality: The shift to an integrated biorefinery model (sugar, ethanol, maize, rice) allows the company to pivot between feedstocks based on prevailing market economics.
• Expansion Readiness: Successful commissioning of the 200 KLPD grain-based distillery provides new capacity to address demand.

Concerns and Watch Points

• Segment Profitability: The integrated sugar and ethanol operations are facing structural headwinds (feedstock costs and tender pricing) leading to widening EBITDA losses.
• Execution Risk: Future revenue guidance (e.g., Rs 240 crore/quarter for chemicals) is dependent on successful debottlenecking execution.
• External Factors: Future performance remains sensitive to climate effects (rainfall, dam levels) and government policy on ethanol blending and sugar/ethanol pricing.

Investor Takeaway

Godavari Biorefineries is navigating a transitional phase, leveraging its strong bio-based chemicals business to offset operational pressures in its traditional sugar and ethanol segment. The management's focus on operational flexibility—through debottlenecking and fungible capacity—and R&D milestones remains the core growth narrative. Shareholders should monitor segment-level margins, the successful execution of planned debottlenecking capex, and any regulatory shifts in ethanol blending policies.

Key Highlights

Strategic IP Development

The company announced that the European Patent Office (EPO) has granted a patent for its pharmaceutical composition. This development is part of the company's ongoing efforts to strengthen its oncology-focused intellectual property portfolio. The grant provides legal protection for the invention, which relates to a novel pharmaceutical composition and the process to prepare it.

Technology and Applications

The patented invention focuses on enhancing the therapeutic potential of anti-cancer compounds. By combining novel anti-cancer compounds with a solubilising agent, the composition is designed to improve the solubility and bioavailability of these active compounds when administered orally. The technology has specific applications in the treatment and management of various cancers, including breast and prostate cancers.

Management Perspective

Management highlighted that this invention significantly contributes to the company's oncology-focused intellectual property portfolio. This reflects a strategic commitment to R&D-led innovation in pharmaceutical formulations.

What Looks Positive

• R&D Validation: The successful grant of a European patent serves as an independent validation of the company's research in drug delivery enhancement and pharmaceutical formulations.
• IP Strength: Securing international patent rights enhances the company's defensive and potentially offensive capabilities in the oncology market, offering a stronger position for future commercialization or licensing strategies.

Investor Takeaway

For investors, this patent grant is a qualitative milestone reflecting the company's progress in pharmaceutical research. While patent grants do not immediately translate to revenue, they are essential building blocks for long-term value creation in the biotech and pharmaceutical sectors. Investors should monitor whether the company advances this technology toward commercialization or explores licensing partnerships in the future.

Upcoming Investor Interaction

Godavari Biorefineries Ltd has announced its participation in the upcoming 'Emkay Confluence 2026 – India: Full Throttle Ahead' investor conference. The company will engage in a physical group meeting with analysts and institutional investors.

Regulatory Disclosure

The company has filed this intimation in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Management has clarified that all discussions during this event will be strictly based on information that is already in the public domain. The company has confirmed that no unpublished price-sensitive information (UPSI) is intended to be discussed or shared during the interaction.

Earnings Conference Call Recording

Godavari Biorefineries Ltd has filed the audio recording of its earnings conference call for the quarter ended Q1 FY27. This release is part of the company's compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Access to Management Commentary

The audio file is available on the company’s official website and provides investors with direct access to management’s explanations, analyst interactions, and strategic commentary regarding the quarter's performance. Reviewing the recording can offer context on the business environment and management's future outlook.

Investor Takeaway

This is a standard disclosure for information and records. Investors interested in the specifics of the Q1 FY27 earnings call may access the provided link on the company's website to listen to the session. No new material information or financial impacts arise directly from this filing.

Financial Results Notification

The company has completed the mandatory newspaper publication of its Un-Audited Financial Results for the quarter ended June 30, 2026. This filing serves as a formal confirmation that the financial statements, having been reviewed and approved by the Board of Directors on August 05, 2026, are now publicly available for stakeholder review.

Regulatory Compliance

This publication is in adherence to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparent communication of financial outcomes and governance disclosures to all market participants.

Investor Access

Interested parties can access the full Un-Audited Standalone and Consolidated Financial Results, along with the Limited Review Report, through the following official channels:

• Company Website: www.godavaribiorefineries.com
• BSE Website: www.bseindia.com
• NSE Website: www.nseindia.com

A QR code has been provided in the official notice for direct digital access to the financial documents.

Key Highlights

Financial Snapshot

The company reported consolidated revenue from operations of ₹557.9 crore for Q1 FY27, representing a year-on-year growth compared to ₹533.2 crore in Q1 FY26. Total income for the quarter stood at ₹559.9 crore.

However, profitability faced pressure during the quarter. Consolidated EBITDA fell to ₹2.6 crore from ₹6.5 crore in the prior year period. Consequently, the net loss widened to ₹19.3 crore from ₹16.0 crore in Q1 FY26.

Segment Performance

The Bio-based Chemicals segment demonstrated stability, reporting revenue of ₹168.7 crore and an EBITDA of ₹19.2 crore, reflecting an EBITDA margin of 11.4%. In contrast, the Integrated Sugar, Co-gen & Ethanol segment, which remains the larger contributor by revenue at ₹377.9 crore, reported an EBITDA loss of ₹14.6 crore.

Operational Update

During the quarter, the company successfully commissioned a 200 KLPD corn/grain-based distillery at Sameerwadi, Karnataka. This move increases the company's total ethanol capacity to 800 KLPD. This initiative is designed to provide dual-feedstock flexibility, allowing the company to process both sugarcane and grain, which is expected to help manage transitions based on seasonal raw material availability.

What This Means for Investors

For investors, the results highlight a mixed performance. The top-line growth and the successful commissioning of new capacity are strategic positives that may enhance future operational flexibility and resilience against feedstock volatility. However, the widening net loss and the EBITDA loss in the sugar segment indicate prevailing operational headwinds that are impacting profitability. Tracking the ability of the new capacity to improve utilization and margins in the coming quarters will be essential.

Investor Takeaway

Godavari Biorefineries continues to expand its manufacturing footprint and diversify its feedstock capabilities, notably through its new grain-based distillery. While the Bio-based Chemicals segment continues to contribute positively to margins, the overall financial results reflect current sector challenges. Investors should monitor the company's progress in utilizing its expanded capacity and its management of raw material costs to drive a turnaround in profitability.

Key Highlights

Godavari Biorefineries released its financial results for Q1 FY27, showcasing operational expansion and segment growth despite external industry headwinds.

Financial Snapshot

Bio-based Chemicals Performance

The bio-based chemicals segment emerged as a highlight, reporting a 53% YoY EBITDA growth. The segment's EBITDA margin expanded to 11.4% in Q1 FY27, compared to 8.9% in Q1 FY26. This indicates effective debottlenecking and a strategic focus on higher-value specialty products within the portfolio.

Operational and Expansion Updates

During the quarter, the company successfully commissioned a 200 KLPD grain-based distillery at Sameerwadi. This strategic move increases total ethanol capacity to 800 KLPD, enhancing the company’s feedstock flexibility and allowing for better operation optimization under varying market conditions.

Research and Development

The company achieved significant R&D milestones:

• Secured an Indian patent for a cost-effective process to manufacture branched alcohols.
• Received a Japanese patent for a novel anti-cancer molecule.
• Filed with the CDSCO to initiate preliminary efficacy trials for a lead anti-cancer molecule targeting Triple Negative Breast Cancer, with trials expected from Q3 FY27.

Financial Management

Finance costs were reported at ₹13.9 crore for Q1 FY27, reflecting a reduction compared to the previous year, which is a positive note for the balance sheet management.

Investor Takeaway

Godavari Biorefineries showed resilience in revenue growth despite industry headwinds. While the company faces profitability pressures with a consolidated net loss, the strong performance of the bio-based chemicals segment and the expansion of ethanol capacity are key operational positives. Investors should track how the company leverages this expanded capacity and R&D progress to drive future value as it manages the current industry challenges.

Key Highlights

Financial Snapshot (Consolidated)

Segment Performance Analysis

The company operates across multiple segments, which face varying seasonal impacts. For the quarter ended June 30, 2026, the operating performance was mixed:

The 'Bio based Chemicals' segment was the only listed operational segment to report a profit during this quarter, acting as a buffer against losses in the Sugar, Cogeneration, and Distillery segments.

Management Commentary

Management has explicitly noted that certain business segments are seasonal in nature and impact the results significantly in specific quarters. They have cautioned that these quarterly figures are not necessarily representative of the company's annual performance.

Investor Takeaway

Godavari Biorefineries' Q1 FY26 results show a transition to a net loss of ₹19.32 crore on a consolidated basis. Investors should prioritize the company's guidance regarding the seasonal nature of its business, which leads to substantial quarterly fluctuations. While core segments like Sugar and Distillery reported operational losses, the Bio-based Chemicals division continues to provide profit. The upcoming 71st Annual General Meeting on September 28, 2026, will be the next key event for shareholders to track corporate governance and future strategic updates.

Key Highlights

Financial Snapshot (Consolidated)

Revenue and Income Analysis

The company reported consolidated revenue from operations of ₹557.88 crore (₹55,787.70 lakh) for the quarter ended June 30, 2026, marking an increase from the ₹533.24 crore (₹53,323.63 lakh) reported in the same quarter of the previous year.

Profitability Analysis

The company reported a net loss of ₹19.32 crore (₹1,931.96 lakh) for the quarter ended June 30, 2026, compared to a net loss of ₹16.02 crore (₹1,601.68 lakh) in the corresponding quarter of the previous year. The Basic Earnings Per Share (EPS) for the quarter stood at (₹3.78).

Management and Business Context

Management has clarified that several business segments are seasonal in nature. Consequently, the results for this quarter are not necessarily representative of the company's overall annual performance. Investors are advised to consider this seasonality when evaluating the quarterly figures.

Corporate Action Details

The Board of Directors has approved the notice convening the 71st Annual General Meeting (AGM) of the company. The meeting is scheduled to be held on September 28, 2026, and will be conducted through Video Conferencing.

What This Means for Investors

The company demonstrated top-line growth compared to the same quarter last year; however, the bottom line remains under pressure with a widened net loss. The management's explicit note on the seasonal nature of its business segments is a key watch point, suggesting that quarterly volatility is inherent to the company's operations.

Investor Takeaway

Investors should monitor the impact of seasonal factors on future quarterly earnings. While revenue shows resilience, the company's ability to manage costs and turn profitability around remains a focal point. The upcoming AGM on September 28, 2026, serves as the next major engagement point for shareholders.

Key Highlights

Management Participation

The earnings conference call will feature senior leadership to discuss the company's financial and operational performance for the quarter ended June 30, 2026. The company has confirmed the following speakers:

• Mr. Samir Somaiya: Chairman & Managing Director
• Mr. Ashish Sinha: AGM, Investor Relations & Finance

What This Means for Investors

This announcement serves as a standard administrative update regarding the upcoming quarterly earnings interaction. It confirms the timing and leadership presence for the scheduled conference call. Investors typically use such calls to gain clarity on the quarter's financial results and hear management's perspective on business operations.

Investor Takeaway

The earnings call scheduled for August 7, 2026, provides a platform for stakeholders to engage with the management team. Investors interested in the company's Q1 FY27 performance should note the date and time for participation. As no price-sensitive information is disclosed in this notice, shareholders should look forward to the actual results discussion during the scheduled call.

Board Meeting Details

Godavari Biorefineries Limited has informed the stock exchanges that a meeting of its Board of Directors is scheduled for Wednesday, August 5, 2026. The primary purpose of this meeting is to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.

This filing is in compliance with Regulation 29(1)(a) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Trading Window Closure

In line with the company’s Insider Trading Code and SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities is currently closed.

• Effective From: July 1, 2026
• Duration: Until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026.
• Applicability: The closure applies to all Directors, Key Managerial Persons, Designated Persons, and their immediate relatives.

Investor Relevance

This notification is a standard procedural requirement and does not contain specific financial performance data. Shareholders and market participants should note August 5, 2026, as the date when the company will disclose its financial performance for the first quarter of the fiscal year 2027.

Regulatory Compliance

Godavari Biorefineries Ltd has filed the compliance certificate for the quarter ended 30th June 2026, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

The certificate was issued by the company’s Registrar and Share Transfer Agent (RTA), MUFG Intime India Pvt. Ltd. (formerly known as Link Intime India Pvt. Ltd.).

Key Confirmation

The RTA has confirmed the following actions regarding share dematerialization for the quarter:

• Processing: All securities received for dematerialization were processed and confirmed (accepted/rejected) to the depositories.
• Listing: Securities comprised in the certificates were listed on the stock exchanges where the company's earlier issued securities are listed.
• Verification: Certificates received for dematerialization were mutilated and cancelled after due verification.
• Registry Update: The register of members has been updated with the names of the depositories as the registered owner within the prescribed timelines.

What This Means for Investors

This filing is a routine corporate governance and regulatory requirement. It serves to confirm that the company and its RTA are adhering to standard operational procedures regarding the dematerialization of shares. It does not carry implications for the company's financial performance, business strategy, or operational outlook.

Summary

• Godavari Biorefineries Ltd. has informed the stock exchanges (NSE and BSE) that it does not meet the criteria to be classified as a 'Large Corporate'.
• This status is in relation to the framework for raising funds via debt securities, as outlined by SEBI.
• The company cited the inapplicability of a specific SEBI circular (dated August 10, 2021) to its operations.

Key Numbers & Dates

• Declaration Date: April 30, 2026
• Referenced SEBI Circular: SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021.

What Changes for the Business

• The company will not be subject to the specific fundraising regulations applicable to 'Large Corporates' under the mentioned SEBI framework.

In compliance with SEBI Regulations 30 and 47, Godavari Biorefineries Limited released a newspaper publication on April 23, 2026. This announcement pertains to a "Special Window for Re-lodgement of Transfer Request of Physical Shares," following SEBI Circular No. H0/38/13/11(2)/2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The window is for shareholders needing to re-lodge transfer requests that were initially rejected or returned.

Summary

• Godavari Biorefineries Limited has submitted a SEBI compliance certificate for the quarter ending March 31, 2026.
• The certificate, issued by its Registrar and Share Transfer Agent, MUFG Intime India Private Ltd, confirms adherence to SEBI (Depositories and Participants) Regulations, 2018.

Key Numbers & Dates

• Quarter End Date: March 31, 2026
• Registrar Certificate Date: April 1, 2026
• Company Filing Date: April 14, 2026

Summary

• Godavari Biorefineries Ltd. announced a record sugarcane crushing of 2.5 million tonnes for the 2025-26 session at its Sameerwadi unit.
• This volume represents the highest ever achieved by the company in a single crushing session.
• The current crushing session is scheduled to conclude on April 7, 2026.

Key Numbers & Dates

• Highest Sugarcane Crushing: 2.5 million tonnes (Session 25-26, Sameerwadi unit)
• Crushing Session End Date: April 7, 2026

What Changes for the Business

• The record crushing volume indicates strong operational performance and efficiency at the Sameerwadi unit.

What to Track Next

• Completion of the current crushing session on April 7, 2026.

Summary

• Godavari Biorefineries Ltd. has informed stock exchanges about the closure of its trading window for dealing in the company's securities.
• The trading window is applicable to Directors, Key Managerial Persons, Designated Persons of the Company and their Immediate Relatives/dependents.
• It will be effective from April 1, 2026, and will remain closed until 48 hours after the declaration of the financial results for the quarter and year ending March 31, 2026.

Key Numbers & Dates

• Trading Window Closure Start Date: 1st April, 2026
• Financial Year End: 31st March 2026
• Report Date: 24th March, 2026

What Changes for the Business

• This announcement ensures compliance with SEBI's "Insider Trading Prohibition Code" and related regulations.
• It restricts trading activities by company insiders during a sensitive period leading up to and immediately following financial result announcements.

What to Track Next

• The date of consideration of the Financial Results for the quarter and year ending 31st March 2026, which will be intimated in due course.

Summary

• Godavari Biorefineries Ltd has received a significant patent grant from the Japan Patent Office for its invention related to treating viral infections.
• The granted patent strengthens the company's intellectual property portfolio in Japan.
• The invention involves the use of specific compounds that inhibit V-ATPase activity.

Key Numbers & Dates

• Patent Application Number: 2022-568620
• Patent Number: 7824889
• Patent Application Filing Date: May 10, 2021
• Patent Grant Date: February 25, 2026
• Announcement Date: March 10, 2026

What Changes for the Business

• The patent grant reinforces Godavari Biorefineries' intellectual property rights in Japan, potentially creating barriers for competitors.
• This development is expected to enhance the value of the company's existing and future product pipeline in the antiviral therapeutics sector.

This news report compiles newspaper clippings from February 27, 2026, featuring significant corporate announcements. Oasis Tradelink Limited published details for its upcoming Extra Ordinary General Meeting and e-voting process. GFL Limited announced a postal ballot and e-voting period for member approval on resolutions like director appointments. Godavari Biorefineries Limited informed shareholders about a special window for re-lodging rejected physical share transfer deeds. Additionally, Utkarsh Small Finance Bank released a corrigendum clarifying details for a meeting of unsecured creditors. These announcements are compliant with SEBI and MCA regulations.

Godavari Biorefineries Limited has issued a newspaper publication concerning a "Special Window for Re-lodgement of Transfer Request of Physical Shares." This announcement is made in accordance with Regulations 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. HO/38/13/11(2)/2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The notice was published in the Financial Express (English) and Mumbai Lakshdeep (Marathi) on February 27, 2026.

🧾 Concall Snapshot

• Company/Period/Date: Godavari Biorefineries Limited, Q3 & 9M FY26, February 19, 2026.
• Who spoke: Samir Somaiya (CMD) and Ashish Sinha (AGM, IR & Finance).

🗣️ Prepared Remarks Highlights

• Profitability: Q3 EBITDA grew by ~14% YoY; PBT (pre-exceptional) rose 152.2% to INR 21.4 crores.
• Cost Control: Finance costs declined by 48% YoY due to balance sheet strengthening.
• Chemical Segment: Bio-based chemical EBITDA margins expanded to 7.7% from 4.5% YoY, driven by specialty products.
• Consumer Business: The Jivana brand portfolio crossed INR 100 crores in revenue during 9M FY26.
• R&D: Secured a US patent for an anti-cancer molecule; Sathgen Therapeutics LLC incorporated in the US for out-licensing.

🎯 Guidance & Outlook

• EBITDA Target: Management reaffirmed a target to achieve 3x EBITDA by FY29 (relative to FY25 base).
• Capex: Estimated at INR 325 crores, with 75% allocated to high-margin bio-based chemicals and 25% to ethanol.
• Capacity: The grain-based distillery commissioning is now expected in March or early April 2026.

❓ Investor/Analyst Q&A (ALL QUESTIONS)

• Q1 (Feedstock Risk): Management is mitigating feedstock risks by creating multi-feedstock facilities (maize/grain/cane) for ethanol production.
• Q2 (Capex): Confirmed INR 325cr capex split 75/25 between chemicals and ethanol.
• Q3 (OMC Tenders): Despite rising cane costs, margins remain positive; sourcing is being optimized.
• Q4 (Project Delay): Grain-based distillery delayed to next quarter due to vendor equipment delays.
• Q5 (Pricing Expectations): Industry is requesting price increases for B-heavy and juice-based ethanol to offset cane cost hikes.
• Q6 (Cancer Molecule): Frugal investment of INR 18cr so far; safety trials complete; seeking partners for out-licensing.
• Q7 (Retail Reach): Reached 7,500+ outlets; future brand spend estimated in single-digit crores.
• Q8 (FY29 Targets): Reaffirmed 3x EBITDA growth target over 4 years.
• Q9 (Exceptional Items): Provisions made for Maharashtra harvesting costs and the new national labour code.
• Q10 (Ethanol Market): Bullish on the green transition; domestic supply of 17bn liters supports future ambitious blending targets.

⚠️ Risks & Red Flags

• Margin Compression: Higher cane prices vs. stagnant ethanol prices pose a significant risk to distillery margins.
• Execution Risk: Delays in equipment receipt from vendors pushed the commissioning of the grain-based facility out of the current quarter.
• Regulatory Uncertainty: Profitability is sensitive to government-controlled ethanol pricing and blending mandates.

🧠 Retail Investor Takeaway

Godavari Biorefineries is successfully shifting its product mix toward higher-margin bio-based chemicals and consumer branding (Jivana), leading to sharp profit growth despite a 48% drop in finance costs. While the grain-based ethanol expansion faces minor vendor delays and margins are pressured by rising cane costs, the company's long-term goal of tripling EBITDA by FY29 remains the core focus, supported by disciplined R&D spending.

News Crux

• Godavari Biorefineries Limited has uploaded the audio recording of its earnings conference call for the third quarter (Q3) and nine months (9M) of FY26.

Quarterly Results

This announcement does not contain specific financial results. It refers to the availability of the conference call recording where these results were discussed.

Guidance & Strategy

No guidance or strategy details are provided in this announcement. The recording itself would contain this information.

Financial Deep Dive

No financial deep dive information is present in this notification.

⚠️ Investor Risks & Governance

No risks or governance issues are mentioned. The announcement is a routine disclosure.

Key Events

• Upload of the Q3 and 9M FY26 earnings conference call audio recording to the company website.

Outlook

No outlook is provided in this notification.

News Crux

This document is an investor presentation by Godavari Biorefineries Limited for Q3 and 9M FY26, detailing financial performance, segment highlights, and strategic initiatives.

Quarterly Results

Consolidated Performance:Q3 FY26 vs Q3 FY25 (Year-on-Year):

• Total Income: ₹461.9 Crs vs ₹450.8 Crs (+2.5%)
• EBITDA: ₹45.1 Crs vs ₹39.7 Crs (+13.8%). EBITDA Margin: 9.8% vs 8.8% (+100 bps).
• PBT (before exceptional items): ₹21.4 Crs vs ₹8.5 Crs (+152.3%). PBT Margin: 4.6% vs 1.9%.
• Finance Costs: ₹10.2 Crs vs ₹18.9 Crs (-46.0%).
• Exceptional Expenses: ₹7.9 Crs (implementation of new labor laws) in Q3 FY26.
• Profit/(Loss) after Tax (incl. one-time impact of Deferred Tax): ₹8.3 Crs vs ₹5.8 Crs (+43.2%). PAT Margin: 1.8% vs 1.3%.

Q3 FY26 vs Q2 FY26 (Quarter-on-Quarter):

• Total Income: ₹461.9 Crs vs ₹430.8 Crs (+6.8%)
• EBITDA: ₹45.1 Crs vs ₹(4.4) Crs (Significant turnaround).
• PBT (before exceptional items): ₹21.4 Crs vs ₹(30.2) Crs.
• Exceptional Expenses: ₹7.9 Crs in Q3 FY26 vs ₹26.7 Crs (additional harvesting charges) in Q2 FY26.

9M FY26 vs 9M FY25 (Year-on-Year):

• Total Income: ₹1,430.2 Crs vs ₹1,298.2 Crs (+10.2%)
• EBITDA: ₹47.2 Crs vs ₹(1.4) Crs (Turnaround from loss to profit). EBITDA Margin: 3.3% vs (0.1%).
• PBT (before exceptional items): ₹(31.2) Crs vs ₹(97.3) Crs (Loss narrowed substantially).
• Finance Costs: ₹37.8 Crs vs ₹58.7 Crs (-36.1%).
• Exceptional Expenses: ₹34.5 Crs in 9M FY26.
• Profit/(Loss) after Tax (incl. one-time impact of Deferred Tax): ₹(49.4) Crs vs ₹(95.3) Crs (Loss narrowed). PAT Margin: (3.5%) vs (7.3%).

Guidance & Strategy

The company outlines its guiding principles focused on growth, sustainability, and inclusivity. Key strategic themes include:

• India: Transition to Green Energy: Focus on increasing revenue from Bio-Based Specialty Chemicals, enhancing capacity and utilization in Ethanol, and diversifying feedstock for Ethanol production with a new 200 KLPD grain/maize distillery to be commissioned in Q1 FY27.
• Global: Transition to Green Chemistry: Continued focus on Bio-based Chemicals, increasing the proportion of specialty chemicals, and implementing de-bottlenecking initiatives.
• Innovation: Progress on CO₂-to-DME technology pilot project and incorporation of Sathgen Therapeutics LLC for cancer drug IP marketing.

Financial Deep Dive

• Income Statement Drivers: Revenue growth in Q3 FY26 was supported by the Sugar & Co-Generation segment (+36.1% YoY) and Bio-based Chemicals (+3.8% YoY). The Ethanol segment revenue declined 23.6% YoY in Q3 but grew 29.5% YoY in 9M FY26. EBITDA margin improvement was notable in Bio-based Chemicals (+317 bps in Q3 FY26) and overall consolidated margin expansion.
• Exceptional Items: ₹7.9 Crs in Q3 FY26 due to new labor laws. ₹26.7 Crs in Q2 FY26 for additional harvesting charges. Total 9M FY26 exceptional expenses were ₹34.5 Crs.
• Finance Costs: Reduced significantly by 46.0% YoY in Q3 FY26 and 36.1% YoY in 9M FY26, attributed to term debt repayment of ₹240 Cr from IPO proceeds.

⚠️ Investor Risks & Governance

No explicit auditor qualifications, legal threats, or governance issues were highlighted in the provided text. The 'Safe Harbor' statement contains standard forward-looking disclaimer language.

Key Events

• Incorporation of Sathgen Therapeutics LLC in the United States as a wholly owned subsidiary to market Cancer Drug IP.
• Collaboration with Synthomer for the production of bio-butanol-based Butyl acrylate.
• CO₂-to-DME technology pilot project is progressing as planned.
• Commissioning of a 200 KLPD fungible Grain/Maize distillery in Q1 FY27, expected to add 60 million litres of Ethanol Capacity per annum.

Outlook

The company emphasizes its focus on sustainability and innovation, aiming to leverage green transitions in India and globally. The strategic direction is towards increasing the contribution of high-margin specialty chemicals and expanding Ethanol capacity. The progress in CO2-to-DME technology and drug discovery initiatives through Sathgen Therapeutics point towards future growth avenues.

This report compiles newspaper publications detailing the unaudited financial results for the quarter and nine months ended December 31, 2025, from multiple companies. Firms such as KRONOX Lab Sciences Limited, Shah Alloys Limited, Ice Make Refrigeration Limited, Tolins Tyres Limited, and Godavari Biorefineries Limited have adhered to SEBI (Listing Obligations and Disclosure Requirements) Regulations by publishing these results. The detailed financial statements and limited review reports are available on the respective company websites and stock exchange portals.

This report compiles newspaper publications of unaudited financial results for various companies for the quarter and nine months ended December 31, 2025. Godavari Biorefineries Limited is highlighted with its symbol GODAVARIB and code 544279. The news also covers financial updates from AYM Syntex Limited, Jainex Aamcol Limited, and Balaji Telefilms, among others, as filed with stock exchanges.

News Crux

• CARE Ratings, as the Monitoring Agency for Godavari Biorefineries' ₹325 crore IPO, has submitted its final report for the quarter ended December 31, 2025.
• The report notes a minor deviation of ₹0.09 crore in the utilization of IPO proceeds, with ₹324.91 crore transferred to the monitoring account out of the total ₹325.00 crore gross proceeds.
• The company revised its objects, reclassifying ₹3.37 crore from issue expenses to general corporate purposes (GCP) through board resolutions and legal counsel.
• The report also disclosed that Godavari Biorefineries incurred consolidated net losses of ₹23.41 crore in FY25 and ₹57.61 crore in H1FY26, impacting investor sentiment.
• Comingling of funds in cash credit accounts used for utilization is noted.

Financial Deep Dive

• Consolidated Net Loss: The company reported a consolidated net loss of ₹23.41 crore for the financial year ended March 31, 2025, a decline from a net profit of ₹12.30 crore in FY24.
• H1 FY26 Performance: The net loss continued in the first half of FY26, amounting to ₹57.61 crore.
• Exceptional Items (FY25): The FY25 loss of ₹23.41 crore includes a one-time notional additional deferred tax liability of ₹24 crore as per IndAS, related to land revaluation.

⚠️ Investor Risks & Governance

• [Compliance] IPO Proceeds Deviation: A minor deviation of ₹0.09 crore (0.03%) was observed in the total IPO proceeds transferred to the monitoring account.
• [Governance] Reclassification of Funds: ₹3.37 crore originally earmarked for issue expenses has been reclassified to General Corporate Purposes (GCP) via board resolutions and legal opinion.
• [Compliance] Comingling of Funds: Funds transferred from the monitoring account to cash credit accounts for utilization are comingled with other debits and credits, making precise tracking difficult.
• [Performance] Net Losses: The company reported significant consolidated net losses for FY25 (₹23.41 crore) and H1FY26 (₹57.61 crore), indicating poor financial performance.
• [Compliance] Monitoring Report: This is the final monitoring agency report for the IPO, implying the conclusion of this compliance phase.

Key Events

• This report marks the conclusion of the Monitoring Agency's oversight for the ₹325.00 crore Initial Public Offering (IPO) of Godavari Biorefineries Limited.

News Crux

The Board of Directors of Godavari Biorefineries Limited, at its meeting held on February 13, 2026, considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine months ended December 31, 2025. These results were reviewed by the Audit Committee and underwent a limited review by the Statutory Auditors.

Quarterly Results

Consolidated Results:

• Revenue from operations for Q3 FY26 stood at ₹459.85 Crores, a YoY increase of 2.81% from ₹447.27 Crores in Q3 FY25. Sequentially, revenue grew 6.76% from ₹430.75 Crores in Q2 FY26.
• Net Profit after tax (excluding one-time impact of deferred tax) for Q3 FY26 was ₹8.25 Crores, showing a significant YoY growth of 43.2% from ₹5.76 Crores in Q3 FY25. This marks a substantial improvement from a Net Loss of ₹41.59 Crores in Q2 FY26.
• Basic EPS for Q3 FY26 was ₹1.61, up from ₹1.31 in Q3 FY25.
• Total Comprehensive Income for Q3 FY26 was ₹5.81 Crores, a YoY increase of 5.8% from ₹5.49 Crores in Q3 FY25.
• For the Nine Months Ended December 31, 2025, the consolidated Net Profit after tax (excluding one-time impact) was a loss of ₹49.36 Crores, an improvement from a loss of ₹70.84 Crores in the same period last year. The consolidated Basic EPS for the nine months was ₹(9.64), improved from ₹(21.61) YoY.

Standalone Results:

• Revenue from operations for Q3 FY26 was ₹456.08 Crores, up 2.41% YoY from ₹445.37 Crores in Q3 FY25. Sequentially, revenue grew substantially by 99.96% from ₹228.09 Crores in Q2 FY26.
• Net Profit after tax (excluding one-time impact of deferred tax) for Q3 FY26 was ₹8.10 Crores, a YoY increase of 32.57% from ₹6.11 Crores in Q3 FY25. This is a strong rebound from a Net Loss of ₹42.63 Crores in Q2 FY26.
• Basic EPS for Q3 FY26 was ₹1.58, up from ₹1.38 in Q3 FY25.
• Total Comprehensive Income for Q3 FY26 was ₹7.44 Crores, a YoY increase of 19.58% from ₹6.22 Crores in Q3 FY25.
• For the Nine Months Ended December 31, 2025, the standalone Net Profit after tax (excluding one-time impact) was a loss of ₹51.18 Crores, an improvement from a loss of ₹72.74 Crores in the same period last year. The standalone Basic EPS for the nine months was ₹(10.00), improved from ₹(16.48) YoY.

Exceptional Items:

• Q3 FY26 (Consolidated & Standalone): ₹7.88 Crores (₹787.72 Lakhs) recognized towards the estimated impact of New Labour Codes (Note 4).
• 9M FY26 (Consolidated & Standalone): ₹34.53 Crores (₹3,453.31 Lakhs) recognized towards the estimated impact of New Labour Codes (Note 4).
• Q3 FY25 (Consolidated & Standalone): ₹26.66 Crores (₹2,665.59 Lakhs) was recognized for additional harvesting charges (Note 3).

Financial Deep Dive

• Consolidated Total Assets as of December 31, 2025, were ₹1,65,541.90 Lakhs. This is a decrease from ₹1,95,508.90 Lakhs as of March 31, 2025.
• Consolidated Total Liabilities as of December 31, 2025, were ₹92,269.32 Lakhs. This is an increase from ₹1,17,312.45 Lakhs as of March 31, 2025.
• Standalone Total Assets as of December 31, 2025, were ₹1,60,217.21 Lakhs. This is a decrease from ₹1,87,460.85 Lakhs as of March 31, 2025.
• Standalone Total Liabilities as of December 31, 2025, were ₹91,780.03 Lakhs. This is an increase from ₹1,17,122.65 Lakhs as of March 31, 2025.
• The company confirmed in Note 5 that the IPO proceeds of ₹554.75 Crores have been fully utilized in line with the offer document.

News Crux

Godavari Biorefineries Ltd. announced its consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported improved profitability and margins driven by operating leverage.

Quarterly Results

Consolidated:

• Q3 FY26 vs Q3 FY25 (YoY):
  • Total Income: ₹461.9 Cr vs ₹450.8 Cr (+2.5%)
  • EBITDA: ₹45.1 Cr vs ₹39.7 Cr (+13.8%)
  • EBITDA Margin: 9.8% vs 8.8% (+97 bps)
  • PBT* (before exceptional items): ₹21.4 Cr vs ₹8.5 Cr (+152.2%)
  • PBT Margin* (before exceptional items): 4.6% vs 1.9% (+275 bps)
• 9M FY26 vs 9M FY25 (YoY):
  • Total Income: ₹1,430.2 Cr vs ₹1,298.2 Cr
  • EBITDA: ₹47.2 Cr vs (₹1.4) Cr
  • EBITDA Margin: 3.3% vs (0.1%)
  • PBT* (before exceptional items): (₹31.2) Cr vs (₹97.3) Cr
  • PBT Margin* (before exceptional items): (2.2%) vs (7.5%)
• Exceptional Items: Q3 FY26 recorded an exceptional expense of ₹7.9 Cr related to new labor laws.

Segment Highlights (Consolidated EBITDA):

• Bio Based Chemicals: Q3 FY26 ₹10.9 Cr vs Q3 FY25 ₹6.2 Cr (+76.7%); 9M FY26 ₹38.2 Cr vs 9M FY25 ₹24.3 Cr.
• Ethanol: Q3 FY26 ₹4.2 Cr vs Q3 FY25 ₹9.6 Cr (-56.6%); 9M FY26 ₹22.0 Cr vs 9M FY25 ₹18.1 Cr.
• Sugar & Cogeneration: Q3 FY26 ₹32.1 Cr vs Q3 FY25 ₹25.1 Cr (+28.1%); 9M FY26 (₹8.5) Cr vs 9M FY25 (₹40.5) Cr.

Financial Deep Dive

• Finance costs declined by 46% year-on-year.
• The Bio-based Chemicals segment is a key profit driver, with specialty chemicals contributing 62% of its basket in 9M FY26.
• The company is scaling its retail platform; the Jivana brand crossed ₹100 Cr revenue in 9M FY26.
• A fungible grain-based ethanol capacity is expected to be commissioned in Q1 FY27.

Key Events

• Grant of a U.S. patent for a novel anti-cancer molecule targeting triple-negative breast cancer.
• Pilot plant activities are underway for the DME-to-CO₂ technology initiative.
• Collaboration with Synthomer to develop bio-based alternatives to fossil-based monomers.

Outlook

• The company expects the share of specialty chemicals in the Bio-based Chemicals segment to rise further.
• The new grain-based ethanol capacity in Q1 FY27 positions the company to benefit from ethanol blending program restoration and incremental demand.
• Continued focus on high-potential bio-based specialty chemicals, capacity optimization, and sustainability-led innovation are expected to drive long-term growth.

News Crux

Godavari Biorefineries announced its un-audited financial results for the quarter and nine months ended December 31, 2025. The company reported a turnaround in its quarterly consolidated net profit, while revenue showed year-on-year growth. Standalone quarterly performance also improved significantly.

Quarterly Results

Consolidated:

• Revenue from operations: Q3 FY26: ₹45,985.25 Lakhs (YoY +6.76% vs ₹43,075.08 Lakhs in Q3 FY25). 9M FY26: ₹1,42,383.96 Lakhs (YoY +10.31% vs ₹1,29,074.67 Lakhs in 9M FY25).
• Total Income: Q3 FY26: ₹6,190.85 Lakhs (YoY -95.24% vs ₹1,29,815.53 Lakhs in Q3 FY25). 9M FY26: ₹88,691.38 Lakhs (YoY -36.44% vs ₹1,39,543.28 Lakhs in 9M FY25).
• Net Profit/(Loss) After Tax: Q3 FY26: ₹252.10 Lakhs (YoY turnaround from loss of ₹1,592.40 Lakhs in Q3 FY25). 9M FY26: ₹(761.70) Lakhs (YoY slightly increased loss from ₹(871.37) Lakhs in 9M FY25).
• EPS: Q3 FY26: ₹1.61 (YoY turnaround from ₹(1.31) in Q3 FY25). 9M FY26: ₹(1.92) (YoY increased loss from ₹(1.91) in 9M FY25).

Standalone:

• Revenue from operations: Q3 FY26: ₹45,608.15 Lakhs (YoY +2.41% vs ₹44,536.81 Lakhs in Q3 FY25). Q2 FY26: ₹22,808.60 Lakhs (QoQ +100.00%).
• Total Income: Q3 FY26: ₹45,868.96 Lakhs (YoY +84.62% vs ₹24,843.37 Lakhs in Q3 FY25). Q2 FY26: ₹26,116.00 Lakhs (QoQ +75.63%).
• Net Profit/(Loss) After Tax: Q3 FY26: ₹809.58 Lakhs (YoY turnaround from loss of ₹4,262.69 Lakhs in Q3 FY25). Q2 FY26: ₹(4,262.69) Lakhs (QoQ turnaround).
• EPS: Q3 FY26: ₹1.58 (YoY turnaround from ₹(8.33) in Q3 FY25). Q2 FY26: ₹(8.33) (QoQ turnaround).

Financial Deep Dive

Consolidated: Revenue from operations grew YoY for both Q3 (+6.76%) and 9M (+10.31%). Consolidated Total Income, however, showed a significant YoY decline for Q3 (-95.24%) and 9M (-36.44%), which is inconsistent with revenue growth and raises data integrity concerns. Exceptional expenses of ₹787.72 Lakhs (Q3 FY26) for New Labour Codes and ₹2,665.59 Lakhs (9M FY26) for harvesting charges were recognized. The company achieved a turnaround in consolidated net profit for Q3 FY26 to ₹252.10 Lakhs (vs. loss last year), but the 9M consolidated net loss slightly increased.

Standalone: Revenue from operations grew YoY for Q3 (+2.41%) and 9M (+9.81%). Standalone Total Income surged YoY for Q3 (+84.62%) and grew for 9M (+11.78%). Standalone net profit turned positive in Q3 FY26 at ₹809.58 Lakhs (from a loss YoY) and the standalone net loss for 9M FY26 reduced.

⚠️ Investor Risks & Governance

• [Financial Reporting] Significant inconsistencies noted between consolidated and standalone Total Income figures for 9M FY26, and between consolidated Total Income and Revenue from Operations for Q3 FY26, raising concerns about data integrity.

Key Events

• The company completed its Initial Public Offer (IPO) of equity shares on October 30, 2024, raising ₹554.75 Crores, with proceeds fully utilized.
• Exceptional expenses were recognized: ₹787.72 Lakhs (Q3 FY26) due to New Labour Codes and ₹2,665.59 Lakhs (9M FY26) for additional harvesting charges for the 2023-2024 sugar season.

Godavari Biorefineries Limited (GBL) has disclosed an order from the National Green Tribunal (NGT), Western Zone Bench, Pune, received on February 09, 2026. The NGT has directed GBL to construct a trench of adequate size along the periphery of its bioremediation area within two months. This action is intended to catch runoff water and prevent it from reaching the Godavari River, ensuring such water is routed for treatment at the industry site. This directive follows a complaint filed on March 24, 2024, by Mr. Prasad Haribhau Jadhav, alleging water pollution and contamination of the Godavari river and surrounding water sources near the company's Sakarwadi Manufacturing facility due to alleged discharge of hazardous chemicals and emission of hazardous gases. Crucially, Godavari Biorefineries Limited has explicitly stated that this NGT order has no material impact on the company's financials, operations, or other activities.

Godavari Biorefineries Limited (GBL) has announced a significant strategic partnership with Synthomer plc, a global leader in specialised polymers and ingredients. This collaboration is aimed at developing and commercialising bio-based alternatives to existing fossil-based monomers, a move driven by escalating customer demand for sustainable and lower-carbon solutions. The partnership leverages GBL's expertise in biorefining and its production of bio-based butanol, which will be used by Synthomer to produce bio-based butyl acrylate.

The initiative underscores GBL's deep-rooted commitment to sustainability, integrating it into its core business strategy and innovation agenda. Samir Somaiya, Chairman and Managing Director of GBL, articulated that the collaboration with Synthomer is a testament to their dedication to advancing bio-based alternatives that lead to meaningful reductions in carbon footprints across value chains. He emphasized GBL's strategy of utilizing renewable feedstocks and integrated biorefinery capabilities to support partners and customers in transitioning away from fossil-based materials. This aligns with GBL's vision of creating a more sustainable and circular economy.

Synthomer, headquartered in London, also highlighted the strategic importance of this partnership. Chris Brown, Vice President of ESG at Synthomer, stated that partnering with GBL allows them to offer customers a more sustainable, lower-carbon alternative to traditional monomers. This helps customers meet their own emissions targets and strengthens Synthomer's monomers portfolio by enhancing its resilience and adaptability to evolving market needs. Synthomer itself has a strong focus on sustainability, with its 2030 decarbonisation targets approved by the Science Based Targets initiative.

Godavari Biorefineries Limited is recognized as a pioneer in India's bio-based chemicals and biofuels sector, operating an integrated biorefinery model that produces specialty chemicals, ethanol, and green energy with a reduced environmental impact. The company is listed on both BSE and NSE. Synthomer serves key sectors including coatings, construction, adhesives, and health & protection, with a global presence across Europe, North America, and Asia.

This partnership signifies a step towards greener chemistry and a more circular chemical industry, aligning with global sustainability trends and increasing regulatory focus on reducing environmental impact. No specific financial performance data, quarterly or annual results, or future financial guidance were disclosed in this announcement. The focus remains entirely on the strategic, sustainability-driven nature of this new alliance.

Godavari Biorefineries Limited has formally announced the schedule for its earnings conference call, which will focus on discussing the company's financial and operational performance for the third quarter and the first nine months of the fiscal year 2026 (Q3 and 9MFY26), ending on December 31, 2025. The investor call is slated to take place on Thursday, February 19, 2026, commencing at 11:00 AM Indian Standard Time.

Key management personnel, including Mr. Samir Somaiya, Chairman & Managing Director, and Mr. Ashish Sinha, AGM of Investor Relations & Finance, are expected to lead the discussion. Investors and analysts can join the call using the provided universal dial-in numbers (+91 22 6280 1550 / +91 22 7115 8378) or international toll-free numbers for regions including the USA, UK, Singapore, and Hong Kong. Pre-registration via Diamond Pass is also available.

A significant point of clarification from the company is that 'No unpublished price-sensitive information is proposed to be shared during the meeting/call.' This intimation is being made in compliance with SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015. The details of the conference call, including dial-in information, are also hosted on the company's official website, https://www.godavaribiorefineries.com/. RSVP contacts for the company and its investor relations advisor, MUFG Intime India Pvt Ltd, are provided for logistical purposes.

The news is an intimation from Godavari Biorefineries Limited regarding a forthcoming Board Meeting scheduled for Friday, February 13, 2026. The primary agenda for this meeting will be to consider and approve the company's standalone and consolidated un-audited financial results for the third quarter and the first nine months of the fiscal year 2026, ending on December 31, 2025, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the company has informed about the closure of its trading window for dealing in the company's securities. This window will be shut for all directors, key managerial persons, designated persons, and their immediate relatives from January 01, 2026, and will reopen 48 hours after the declaration of the financial results. No specific financial performance figures, future guidance, or outlook details were provided in this announcement, as it pertains solely to the scheduling of the results declaration and the associated trading window management.

Godavari Biorefineries Limited has officially informed the stock exchanges about the submission of a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate pertains to the quarter ended December 31, 2025. The filing was made by MUFG Intime India Private Ltd, the company's Registrar and Share Transfer Agent. The certificate confirms that all securities received from depository participants for dematerialisation during the quarter were duly processed and confirmed to the depositories. It also assures that the securities are listed on the relevant stock exchanges and that physical certificates received were mutilated and cancelled, with the depositories' names substituted in the company's register of members within the prescribed timelines. This is a routine compliance activity by the company.

Godavari Biorefineries Limited has announced the closure of its trading window for dealing in the company's securities, effective January 1, 2026. This restriction will apply to all Directors, Key Managerial Persons, Designated Persons, and their immediate relatives, and will remain in place until 48 hours after the declaration of the unaudited financial results for the quarter ended December 31, 2025 (Q3 FY26).

This announcement is a routine corporate compliance measure mandated by SEBI regulations to prevent insider trading. While the immediate news pertains to compliance, broader context from recent company communications highlights significant operational and strategic developments.

Financially, Godavari Biorefineries has shown a positive trend in its EBITDA performance, with Q1 FY26 reporting positive EBITDA of ₹6.5 Cr against a loss of ₹9.5 Cr YoY, and Q2 FY26 reducing EBITDA losses to ₹4.4 Cr from ₹31.5 Cr YoY. The company reported consolidated revenue growth of 34.5% YoY to ₹434.3 Cr in Q2 FY26. However, the company continues to report Net Profit After Tax (PAT) losses, though these have reduced year-on-year. For H1 FY26, PAT losses stood at ₹57.6 Cr.

Strategic initiatives are a key focus, including expansion in the bio-based chemicals and ethanol segments. The company is progressing with its 200 KLPD grain/maize distillery expansion, targeting commercial production by Q4 FY26. R&D achievements include securing European and US patents for novel anti-cancer compounds. The company has also established a US subsidiary, Sathgen Therapeutics LLC, to focus on pharmaceutical marketing and business development for its drug discoveries.

Management has outlined long-term targets, including a goal to achieve 3x EBITDA growth by FY29 and an EBITDA margin target of over 15% for specialty chemicals by FY29. The company also launched a pilot project to convert industrial CO2 emissions into Dimethyl Ether (DME).

Key financial ratios like ROCE are around 5.50% and ROE is negative, reflecting the ongoing PAT losses, although Debt/Equity stands at 0.69. An exceptional expense of ₹26.7 Cr related to harvest charges was recognized in Q2 FY26.

Godavari Biorefineries Ltd. has reported its Q2 and H1 FY26 financial results, indicating improved operational performance with revenue growth and reduced losses.

Quarterly/Annual Results: For Q2 FY26, consolidated revenue increased by 34.5% year-on-year to ₹434.3 Cr. EBITDA losses narrowed significantly to ₹(4.4) Cr from ₹(31.5) Cr in Q2 FY25. For H1 FY26, revenue grew 14.3% year-on-year to ₹968.2 Cr, and EBITDA losses reduced to ₹2.1 Cr from ₹(105.7) Cr in H1 FY25. Profit After Tax (PAT) remained in losses at ₹(41.6) Cr for Q2 and ₹(57.6) Cr for H1 FY26, though these losses were reduced year-on-year. An exceptional expense of ₹26.7 Cr related to harvest charges was recognized in Q2 FY26.

Guidance & Concall Commentary: Management has set ambitious targets, aiming for 3x EBITDA growth by FY29 and anticipating specialty chemical EBITDA margins exceeding 15% by FY29. A capital expenditure plan of ₹325 Cr is underway to support this growth. The company's 200 KLPD grain/maize distillery expansion is progressing on schedule for commercial production by end-CY25/Q4 FY26, expected to add 60 million liters of ethanol capacity. Concall transcripts and recordings for the Q2/H1 FY26 results are available.

Financials: The company's balance sheet shows reduced borrowings and improved debtor days. As of Mar 2025, Equity Capital stood at ₹51 Cr and Reserves at ₹721 Cr, with Borrowings at ₹488 Cr. Cash equivalents were ₹21 Cr. In FY25, operating cash flow was negative (-₹1 Cr), but financing activities were positive (+₹63 Cr) due to borrowings and share issuance. Capital expenditure in FY25 was ₹61 Cr. Key ratios indicate ROCE was 6% in Mar 2025, with ROE at -0.41% in Mar 2025. The interest coverage ratio is noted as low.

Key Events:

• R&D/Products: Godavari Biorefineries has secured European and US patents for novel anti-cancer compounds that inhibit unregulated cell growth. They have also launched a pilot project for converting industrial CO2 emissions into Dimethyl Ether (DME), a low-emission fuel and chemical feedstock.
• Expansion: The 200 KLPD grain/maize distillery expansion is on track for completion and commercial production by end-CY25/Q4 FY26.
• Subsidiary: The company announced the incorporation of its overseas wholly owned step-down subsidiary, Sathgen Therapeutics, LLC, in the USA on November 17, 2025. This entity, capitalized at US$350,000, will focus on pharmaceutical marketing and business development for its proprietary drug discoveries.
• Awards: Godavari Biorefineries received the ICC – K. V. Mariwala Award for Effective Chemical Industry-Academia Partnership for its innovative CO2-to-DME technology developed in collaboration with ICT Mumbai.
• Corporate Compliance: On December 26, 2025, the company issued a clarification to BSE regarding significant share price and volume movements, stating that all material information has been disclosed and there is no undisclosed price-sensitive information. The company also appointed Nandan Dhanajay Mehta and Sean E. Reagan as Independent Directors. The trading window was closed from October 1, 2025, until 48 hours post the announcement of Q2/H1 FY26 financial results.

Outlook: Godavari Biorefineries is strategically pivoting towards bio-based specialty chemicals and ethanol, aiming for substantial EBITDA growth by FY29. Continued progress in R&D, particularly in drug discovery and sustainable technologies, forms a key part of its long-term strategy. Expansion into the US market via Sathgen Therapeutics LLC is a significant step towards monetizing its R&D pipeline. While PAT remains negative, the improvement in operational metrics is a positive sign. Management guidance reflects strong growth ambitions, balanced by the need to achieve profitability.

Godavari Biorefineries Ltd. has reported its Q2 and H1 FY26 financial results, indicating improved operational performance with revenue growth and reduced losses.

Quarterly/Annual Results: For Q2 FY26, consolidated revenue increased by 34.5% year-on-year to ₹434.3 Cr. EBITDA losses narrowed significantly to ₹(4.4) Cr from ₹(31.5) Cr in Q2 FY25. For H1 FY26, revenue grew 14.3% year-on-year to ₹968.2 Cr, and EBITDA losses reduced to ₹2.1 Cr from ₹(105.7) Cr in H1 FY25. Profit After Tax (PAT) remained in losses at ₹(41.6) Cr for Q2 and ₹(57.6) Cr for H1 FY26, though these losses were reduced year-on-year. An exceptional expense of ₹26.7 Cr related to harvest charges was recognized in Q2 FY26.

Guidance & Concall Commentary: Management has set ambitious targets, aiming for 3x EBITDA growth by FY29 and anticipating specialty chemical EBITDA margins exceeding 15% by FY29. A capital expenditure plan of ₹325 Cr is underway to support this growth. The company's 200 KLPD grain/maize distillery expansion is progressing on schedule for commercial production by end-CY25/Q4 FY26, expected to add 60 million liters of ethanol capacity. Concall transcripts and recordings for the Q2/H1 FY26 results are available.

Financials: The company's balance sheet shows reduced borrowings and improved debtor days. As of Mar 2025, Equity Capital stood at ₹51 Cr and Reserves at ₹721 Cr, with Borrowings at ₹488 Cr. Cash equivalents were ₹21 Cr. In FY25, operating cash flow was negative (-₹1 Cr), but financing activities were positive (+₹63 Cr) due to borrowings and share issuance. Capital expenditure in FY25 was ₹61 Cr. Key ratios indicate ROCE was 6% in Mar 2025, with ROE at -0.41% in Mar 2025. The interest coverage ratio is noted as low.

Key Events:

• R&D/Products: Godavari Biorefineries has secured European and US patents for novel anti-cancer compounds that inhibit unregulated cell growth. They have also launched a pilot project for converting industrial CO2 emissions into Dimethyl Ether (DME), a low-emission fuel and chemical feedstock.
• Expansion: The 200 KLPD grain/maize distillery expansion is on track for completion and commercial production by end-CY25/Q4 FY26.
• Subsidiary: The company announced the incorporation of its overseas wholly owned step-down subsidiary, Sathgen Therapeutics, LLC, in the USA on November 17, 2025. This entity, capitalized at US$350,000, will focus on pharmaceutical marketing and business development for its proprietary drug discoveries.
• Awards: Godavari Biorefineries received the ICC – K. V. Mariwala Award for Effective Chemical Industry-Academia Partnership for its innovative CO2-to-DME technology developed in collaboration with ICT Mumbai.
• Corporate Compliance: On December 26, 2025, the company issued a clarification to BSE regarding significant share price and volume movements, stating that all material information has been disclosed and there is no undisclosed price-sensitive information. The company also appointed Nandan Dhanajay Mehta and Sean E. Reagan as Independent Directors. The trading window was closed from October 1, 2025, until 48 hours post the announcement of Q2/H1 FY26 financial results.

Outlook: Godavari Biorefineries is strategically pivoting towards bio-based specialty chemicals and ethanol, aiming for substantial EBITDA growth by FY29. Continued progress in R&D, particularly in drug discovery and sustainable technologies, forms a key part of its long-term strategy. Expansion into the US market via Sathgen Therapeutics LLC is a significant step towards monetizing its R&D pipeline. While PAT remains negative, the improvement in operational metrics is a positive sign. Management guidance reflects strong growth ambitions, balanced by the need to achieve profitability.

Godavari Biorefineries Limited (GBL) has announced the incorporation of Sathgen Therapeutics LLC, a wholly owned step-down subsidiary established in Princeton, New Jersey, USA. This strategic move is aimed at strengthening GBL's clinical-stage biotechnology presence on a global scale. The primary focus of Sathgen Therapeutics will be on the worldwide out-licensing of intellectual property (IP) and accelerating the company's drug development programs, particularly in the oncology sector.

The Sathgen Therapeutics initiative originated from research ideas championed by Dr. Sendurai Mani and supported by Mr. Samir Somaiya, Chairman and Managing Director of GBL. The program focuses on discovering and developing novel molecules, with several candidates showing promising preclinical efficacy, especially in triple-negative breast cancer (TNBC) and novel compounds that inhibit cancer stem cells. Patents for these developments have already been secured in key markets including the US, Europe, and China.

Dr. Padmaja Ganapathy has been appointed as the CEO of Sathgen Therapeutics USA, and Dr. Sendurai Mani will serve as the Chief Scientific Officer. The company has also formed a Scientific Advisory Board (SAB) comprising internationally recognized experts like Dr. Razelle Kurzrock and Dr. Massimo Cristofanilli, to guide its clinical development and translational research strategy.

This expansion into the US biotechnology market signifies a long-term growth driver for GBL, aligning with its broader strategy to innovate and contribute to original drug discovery, thereby aiming to improve patient outcomes. This venture complements GBL's existing biorefining businesses and follows recent financial updates which showed revenue growth and reduced EBITDA losses.

Godavari Biorefineries Limited has announced the grant of a United States patent for its invention titled 'COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH' from its Anti-Cancer Research Segment. The patent details novel chemical compounds, their synthesis process, and biological activity, specifically highlighting their efficacy in inhibiting uncontrolled cell proliferation by primarily targeting cancer stem cells.

These compounds have demonstrated strong potential for treating various cancers, including breast and prostate cancer. This US patent grant follows previous progress in their drug discovery endeavors, including European patent validation. The company's strategic focus on R&D in the pharmaceutical and bio-based chemical sectors is underscored by such intellectual property milestones. While the company also operates in bio-based chemicals and ethanol, this patent represents a significant advancement in its diversification strategy into higher-value, research-intensive areas.

This SSL Research morning update for December 5, 2025, provides a snapshot of market expectations and key actionable news for investors. The market is anticipated to open flat ahead of the RBI MPC policy outcome, with attention on rate-sensitive sectors like Auto, Banks, NBFCs, and Realty. Global markets showed mixed performance, with Wall Street ending mixed and Asian indices largely trading in the red.

Significant corporate actions highlighted include British American Tobacco's intention to offload shares worth nearly Rs 3,000 crore in ITC Hotels, a move deemed negative in the short to medium term. Positively, Shriram Pistons & Rings Ltd is set to acquire 100% stake in Antolin Lighting India and Grupo Antolin India for an enterprise value of approximately Rs 1,670 crore, expanding its presence in automotive interior and lighting solutions.

Other key developments include positive medium to long-term prospects for Seamec and Lloyds Engineering due to new pacts in offshore vessel charter and radar technology development, respectively. RailTel Corp and Zen Tech have received work orders and supply orders worth Rs 63.9 crore and Rs 120 crore, respectively, from government entities, while Diamond Power secured a Rs 748 crore order from Adani Green for cable supply. Deepak Nitrite's arm commenced operations at a new Nitric acid plant, a neutral short-term development. Excelsoft Tech's partnership with AQA for AI R&D is viewed positively for the medium to long term.

The report also details the subscription status of ongoing IPOs for Meesho, Aequs, and Vidya Wires, with Aequs showing strong subscription figures. Promoters made significant purchases in TGV Sraac, Greenply Industries, Aarti Pharmalabs, Usha Martin, and Maharashtra Seamless. Numerous stocks experienced price band revisions from 10% to 20% or 5% to 10%. Important corporate actions like ex-demerger dates, ex-rights issues, and shares exiting anchor lock-in periods are listed. Fund flow data for December 4th shows net inflows from DIIs (Rs +3,661.1 crore) and net outflows from FIIs (Rs -1,994.2 crore).

The transcript of Godavari Biorefineries' Q2 and H1 FY26 earnings conference call, held on November 14, 2025, provides insights into the company's performance and strategic direction.

Financial Performance: For Q2 FY26, revenue rose 34% YoY to ₹430.8 Cr, with H1 FY26 revenue up 14% YoY to ₹964 Cr. EBITDA losses narrowed significantly, with Q2 EBITDA at ₹(4.4) Cr (vs. ₹(31.5) Cr YoY) and H1 EBITDA at ₹2.1 Cr (vs. ₹(41) Cr YoY). Gross margins expanded by approximately 4.5% in Q2 and 5% in H1. Net losses persisted, although reduced year-on-year. An exceptional expense of ₹26.7 Cr for harvesting charges was noted as a one-time event.

Segmental Highlights: The Bio-based Chemicals segment saw a 60% increase in EBITDA in Q2, driven by a higher proportion of specialty chemicals. The Ethanol segment achieved positive EBITDA of ₹4.7 Cr in Q2, improving from a loss in the prior year, supported by better blending economics and an upcoming 200 KLPD grain-based distillery set for Q4 FY26 commissioning. The company noted positive industry developments in sugar exports and molasses duty.

Strategic Initiatives & Outlook: Key growth drivers discussed include increasing specialty chemical contribution, expanding ethanol capacity and feedstock flexibility, advancing drug discovery towards out-licensing (with a proposed US subsidiary), and launching a pilot CO2-to-DME project. Management expressed confidence in long-term revenue and EBITDA growth over the next 2-3 years, aiming for EBITDA positivity by FY26, and outlined a ₹325 Cr capex plan by FY29. They are not currently exploring bioplastics but remain open to leveraging agricultural feedstock for various products.

Godavari Biorefineries Limited has issued a newspaper publication on November 19, 2025. This announcement pertains to a special window for the re-lodgement of physical share transfer requests, as per SEBI Circular No. SEBI/HO/MIRSD-PoD/P/CIR/2025/97 dated July 02, 2025. The publication was made in the Financial Express (English), Mumbai Lakshdeep (Marathi), and Vartha Bharati (Kannada).

Godavari Biorefineries Limited has announced a significant strategic expansion with the incorporation of Sathgen Therapeutics, LLC, in the USA on November 17, 2025. This entity, a wholly owned step-down subsidiary funded with US$350,000 in share capital, will focus on pharmaceutical marketing and business development for the company's innovative drug discoveries. This initiative leverages the company's R&D efforts, including its successful acquisition of European patents for novel anti-cancer compounds, and aims to establish an international presence for its pharmaceutical pipeline.

This development follows closely on the heels of the company's Q2 and H1 FY26 financial results, which indicated positive operational momentum. For Q2 FY26, consolidated revenue surged by 34.5% year-on-year to ₹434.3 crore, while EBITDA losses narrowed significantly to ₹4.4 crore from ₹31.5 crore YoY. The first half of FY26 also saw revenue grow 14.3% YoY to ₹968.2 crore, with EBITDA turning positive at ₹2.1 crore from a substantial loss of ₹105.7 crore YoY. Although net losses persisted, the reduction in operational losses and strategic progress, including the ongoing expansion of its 200 KLPD distillery and the CO2-to-DME pilot project, highlight the company's diversified growth strategy. Godavari Biorefineries remains committed to its long-term vision of achieving 3X EBITDA growth by FY29 and enhancing its specialty chemical margins.

Godavari Biorefineries Limited (GBL) has released its Sustainability Report for the Financial Year 2024-25, underscoring its commitment to Environmental, Social, and Governance (ESG) principles. This report follows recent financial disclosures for Q2 and H1 FY26, which indicated a significant year-on-year revenue increase and a contraction in EBITDA losses, while maintaining a focus on its bio-based chemicals and ethanol segments. The company reported standalone revenue growth in FY25, though a net loss was incurred, largely due to a one-time deferred tax expense.

GBL's sustainability efforts span environmental stewardship, including renewable energy adoption (84% of total energy from renewables), water management with Zero Liquid Discharge (ZLD) at all sites, and comprehensive waste management aiming for a circular economy. Social initiatives focus on employee well-being, training (19,180 hours in FY25), diversity, and community development through education and skill-building programs. Corporate governance is highlighted through a structured board composition and adherence to various policies.

Strategically, GBL is expanding its ethanol capacity with a new grain-based distillery targeted for Q4 FY26. The company is also advancing its bio-based specialty chemicals portfolio and its drug discovery program, including European patent validation for an anti-cancer molecule. A key initiative highlighted is the pilot project to convert industrial CO2 emissions into Dimethyl Ether (DME), a low-emission fuel. Management has indicated a long-term target of achieving over 15% EBITDA margin for specialty chemicals by FY29, supported by planned capital expenditure for growth.

Godavari Biorefineries Limited has formally filed its Sustainability Report for the Financial Year 2024-25 with the National Stock Exchange (NSE) and BSE Limited on November 17, 2025. This report, available on the company's website, details its commitment and performance regarding environmental, social, and governance (ESG) factors. The filing occurs subsequent to the company's recently announced Q2 and H1 FY26 financial results. In these results, Godavari Biorefineries reported a 34.5% year-on-year increase in Q2 revenue to ₹434.3 Cr and a significant reduction in EBITDA losses to ₹(4.4) Cr from ₹(31.5) Cr YoY. While PAT remained in losses, the company highlighted strategic advancements including its bio-based chemicals segment expansion, an upcoming 200 KLPD distillery targeted for Q4 FY26, progress in drug discovery with a European patent grant, and the launch of a CO2-to-DME pilot project. Management continues to focus on these growth drivers for long-term value creation.

Godavari Biorefineries Limited has announced the availability of the audio recording for its Q2 and H1 FY26 earnings conference call on its official website, pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This follows the company's recent disclosure of its financial results for the period ended September 30, 2025.

Quarterly/Annual Results: For Q2 FY26, the company reported a substantial 34.5% year-on-year increase in total income, reaching ₹434.3 crore. EBITDA losses were significantly narrowed to ₹4.4 crore, an improvement from ₹31.5 crore in the same quarter last year. For the first half of FY26 (H1 FY26), revenue grew 14.3% YoY to ₹968.2 crore, with EBITDA losses contracting to ₹2.1 crore from ₹105.7 crore YoY. Profit After Tax (PAT) continued to be reported in losses for both periods (₹41.6 crore for Q2 and ₹57.6 crore for H1 FY26), though representing an improvement from prior year figures. An exceptional expense of ₹26.7 crore related to harvesting charges was recognized in Q2 FY26.

Guidance & Concall Commentary: While the recording itself is the primary announcement, prior management discussions have indicated long-term targets including an EBITDA margin exceeding 15% for specialty chemicals by FY29 and a strategic goal of achieving 3x EBITDA growth by FY29. Discussions are expected to have covered progress in the bio-based chemicals and ethanol segments, along with ongoing strategic initiatives.

Financials: The balance sheet shows a reduction in borrowings to ₹488 crore in FY25 from ₹655 crore in FY24, leading to an improved debt-to-equity ratio. However, cash flow from operations was negative at ₹1 crore in FY25. Key financial ratios, including ROCE (6% in FY25) and ROE (-0.41% as of March 2025), remain low, and the interest coverage ratio is weak due to reported losses.

Key Events: Significant ongoing developments include the expansion of its 200 KLPD grain/maize distillery, targeted for commissioning by Q4 FY26. The company has also achieved R&D milestones such as a European patent grant for an anti-cancer molecule and the launch of a pilot project to convert industrial CO2 emissions into Dimethyl Ether (DME). Management received the ICC – K. V. Mariwala Award for its industry-academia partnership with ICT Mumbai, and new directors were appointed at the recent AGM.

Outlook: The company's strategic focus remains on expanding its bio-based chemicals and ethanol businesses, advancing its drug discovery pipeline, and implementing sustainable technologies. These efforts are directed towards achieving its long-term financial and growth objectives.

Godavari Biorefineries Limited has released its investor presentation detailing the Q2 and H1 FY26 financial and operational performance.

Financial Performance (Consolidated):

• Q2 FY26: Total income grew by 34.8% YoY to ₹434.3 Cr. EBITDA losses contracted by ₹27.1 Cr YoY to ₹(4.4) Cr, with the EBITDA margin at (1.0%). Profit After Tax (PAT) loss reduced YoY by ₹22.5 Cr to ₹(41.6) Cr.
• H1 FY26: Total income increased by 14.3% YoY to ₹968.2 Cr. EBITDA turned positive at ₹2.1 Cr, an improvement of ₹107.8 Cr YoY, with an EBITDA margin of 0.2%. PAT loss was ₹(57.6) Cr, an increase of ₹16.6 Cr YoY.

Segmental Highlights:

• Bio-based Chemicals: Revenue grew 23% YoY in Q2 and 8% YoY in H1. EBITDA improved significantly in Q2 FY26.
• Ethanol: Revenue surged 246% YoY in Q2 and 85% YoY in H1. EBITDA for Q2 was ₹4.7 Cr (vs ₹(2.9) Cr YoY), and for H1 was ₹17.8 Cr (vs ₹8.6 Cr YoY).
• Sugar & Co-Generation: This segment reported EBITDA losses in both Q2 and H1 FY26, though the losses contracted YoY.

Key Initiatives & Updates:

• Exceptional Expense: A provision of ₹26.7 Cr has been recognized for additional harvest charges related to the 2023-2024 sugar season.
• Capacity Expansion: The 200 KLPD fungible Grain/Maize distillery is progressing as per plan for Q4 FY26 commissioning, expected to add 60 million litres of ethanol capacity.
• R&D & Innovation: The company received a Clinical Study Report for its novel anti-cancer molecule after concluding Phase I safety trials. A pilot project for CO2-to-DME technology, converting industrial CO2 emissions into a clean fuel, has been launched in collaboration with ICT Mumbai.
• Consumer Brand (Jivana): The brand continues its growth trajectory, with H1 FY26 revenue up 25% and increased store penetration.

Financials:

• Balance Sheet (Consolidated, Sep 25): Total Assets ₹1,463.5 Cr, Total Equity ₹725.1 Cr, Total Liabilities ₹738.4 Cr (including ₹164.7 Cr borrowings).
• Cash Flow (Consolidated H1 FY26): Net Cash from Operating Activities was ₹32.6 Cr. Net decrease in Cash & Cash Equivalents was ₹23.1 Cr.

The company is focused on increasing the proportion of specialty chemicals in its portfolio and enhancing capacity utilization in the ethanol business.

The news covers the announcement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2025, by multiple Indian companies including Melstar Information Technologies Limited, Prabhu Steel Industries Limited, Saraswati Commercial (India) Limited, Eco Recycling Limited, 3i Infotech Limited, and Godavari Biorefineries Limited.

Saraswati Commercial (India) Limited reported a YoY decrease in total income for Q2 FY26 (down 6.43%) and net profit after tax (down 4.78%). However, for the six months ended September 30, 2025, total income increased by 3.52% YoY, and net profit after tax surged by 389.94% YoY. Earnings per share also saw a substantial jump for the six-month period (from 2.12 to 836.66).

Eco Recycling Limited, 3i Infotech Limited, and Godavari Biorefineries Limited all reported a turnaround to profitability in their unaudited results for Q2 and H1 FY26, moving from net losses to net profits. For Q2 FY26, revenue saw a slight YoY decline (around 1.5%), but net profit turned positive. For H1 FY26, revenue increased significantly (over 750% YoY for 3i Infotech and Godavari Biorefineries, and over 600% for Eco Recycling), with net profits turning positive from prior year losses. Earnings per share also turned positive for these companies.

Melstar Information Technologies Limited and Prabhu Steel Industries Limited announced the publication of their un-audited financial results but did not provide specific financial figures in the excerpt.

In addition to financial results, several public notices were issued. These include notices related to property inheritance, sale of shops, and potential auctions of pledged assets. Godavari Biorefineries and 3i Infotech highlighted business development activities, including significant tenders/projects and upcoming public issues, signaling strategic growth initiatives.

Godavari Biorefineries Limited has formally informed the stock exchanges that its Un-Audited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2025, have been published in newspapers. The results were officially announced on November 13, 2025, appearing in the Financial Express and Mumbai Lakshdeep.

Godavari Biorefineries Limited has filed its Monitoring Agency Report for the quarter ended September 30, 2025, with the National Stock Exchange and BSE Limited. This report, prepared by CARE Ratings Limited, details the utilization of proceeds from the company's Initial Public Offering (IPO) of equity shares aggregating to ₹325.00 crore. Key findings from the report, reviewed by the company's Audit Committee and Board of Directors, indicate 'Nil' deviation from the stated objects of the issue. The report confirms that all utilization of funds during the quarter was in line with the disclosures in the Offer Document and the revised cost of objects approved by the Board. A significant point noted is the reclassification of ₹1.46 crore from the surplus of issue expenses to general corporate purposes. This reallocation was approved by the company's Board of Directors on May 24, 2025, and the Monitoring Agency (MA) relied on a legal opinion from the company's counsel, Khaitan & Co., stating that board approval is sufficient for such modification. The company also has board approval to utilize additional surplus of up to ₹2.25 crore for General Corporate Purposes (GCP) as and when required. The report also provides context on the company's financial performance, highlighting a net loss of ₹23.41 crore in FY25 (including a ₹24 crore notional deferred tax liability as per IND-AS) and a net loss of ₹16.02 crore in Q1 FY26. The Q1 FY26 loss was attributed to the sugar division's off-season. As of September 30, 2025, the total unutilized IPO proceeds amounted to ₹2.15 crore. The submission of this report underscores the company's adherence to regulatory compliance concerning the deployment of public issue funds.

Godavari Biorefineries Limited announced its financial results for the quarter and half-year ended September 30, 2025 (Q2 FY26 and H1 FY26), indicating an early recovery. The company reported a consolidated total income of ₹434.3 Cr for Q2 FY26, marking a substantial 34.5% year-on-year (YoY) increase from ₹322.1 Cr in Q2 FY25. For the half-year ended H1 FY26, total income grew 14.3% YoY to ₹968.2 Cr from ₹847.3 Cr.

EBITDA losses significantly narrowed, with Q2 FY26 EBITDA reported at ₹(4.4) Cr compared to a loss of ₹(31.5) Cr in Q2 FY25, reflecting an improved EBITDA margin of -1.0% versus -9.8% YoY. Profit After Tax (PAT) for Q2 FY26 was ₹(41.6) Cr, an improvement from a loss of ₹(75.0) Cr in the prior year, with PAT margin at -9.6% against -23.3% YoY. For H1 FY26, EBITDA improved to ₹2.1 Cr from a loss of ₹(41.0) Cr YoY, and PAT improved to ₹(57.6) Cr from a loss of ₹(101.1) Cr YoY. An exceptional expense of ₹26.7 Cr was recognised in Q2 and H1 FY26 relating to additional harvesting charges for the 2023-2024 sugar season.

Segment-wise, the Ethanol segment showed significant recovery, turning EBITDA positive at ₹4.7 Cr in Q2 FY26 from a loss of ₹2.9 Cr YoY. H1 FY26 Ethanol EBITDA grew by 107% to ₹17.8 Cr. The Bio-based Chemicals segment reported EBITDA of ₹9.4 Cr for Q2 FY26 and ₹18.1 Cr for H1 FY26.

Management commentary highlighted strategic focus on bio-based specialty chemicals and the Ethanol Blending Programme as key drivers. The company is progressing with its drug discovery initiatives, having received a Clinical Study Report for its anti-cancer molecule and a European patent grant for its anti-cancer research segment. Looking ahead, a 200 KLPD fungible grain/maize distillery is targeted for commissioning in Q4 FY26 to enhance feedstock flexibility. In a major sustainability push, a pilot CO₂-to-DME project was launched, converting industrial CO₂ emissions into Dimethyl Ether (DME).

Detailed financial metrics such as balance sheet, cash flow, EPS, and specific ratios were not provided in this release. The company expressed confidence in creating sustainable value through innovation and sustainability-led solutions.

Godavari Biorefineries Limited convened a Board Meeting on November 11, 2025, as per the outcome announced. The meeting, which began at 11:30 AM and concluded at 5:00 PM, focused on the approval of the company's un-audited financial results for the quarter and half-year ended September 30, 2025. These results were approved on both a Consolidated and Standalone basis, adhering to Regulation 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure serves as a follow-up to a previous letter issued by the company on November 3, 2025.

Crucially, this announcement acts purely as a notification of the board's approval and does not contain any specific financial data. Investors seeking to understand the company's performance will not find details on revenue, EBITDA, PAT, EPS, margins, or any year-over-year (YoY) or quarter-over-quarter (QoQ) changes in this filing. Furthermore, there is no information provided regarding management guidance, forward-looking statements, growth drivers, identified risks, or specific commentary from a recent earnings call. The announcement also omits details on balance sheet items, cash flow metrics, key financial ratios (such as ROE/ROCE, debt-to-equity), or order book status. No information regarding dividends, buybacks, product launches, expansions, or penalties is present.

In summary, this news is a procedural update regarding the approval of financial results. A comprehensive financial analysis, performance evaluation against prior periods or market expectations, or insights into the company's outlook and strategic direction cannot be derived from this document. Investors must await the full financial statements and accompanying disclosures for substantive information.

Godavari Biorefineries Limited announced the outcome of its Board of Directors' meeting held on November 11, 2025. The meeting, which lasted from 11:30 AM to 5:00 PM, focused on the review and approval of the company's unaudited financial results for both the second quarter and the first half of the financial year ending September 30, 2025. These consolidated and standalone results, along with the Independent Auditor's Review Report, have been submitted to the National Stock Exchange of India Limited and BSE Limited as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure follows up on a prior communication dated November 3, 2025. The provided announcement does not include specific financial figures, performance comparisons, management guidance, outlook, or detailed financial analysis.

Godavari Biorefineries Limited (GBL), under the leadership of Chairman and Managing Director Samir Somaiya, has announced the launch of a significant pilot project focused on climate action. In partnership with the Institute of Chemical Technology, Mumbai (ICT), GBL is developing and piloting a technology that converts industrial CO2 emissions directly into Dimethyl Ether (DME). DME is a sustainable, clean-burning fuel capable of replacing conventional energy sources like LPG and diesel, thus reducing emissions and aiding decarbonisation. Beyond its fuel applications, DME also serves as a versatile chemical feedstock.

This innovation is highlighted as a step towards addressing India's triple challenge of energy security, climate change, and rural prosperity. The project leverages India's strength in agriculture and renewable energy, aiming to secure farmer incomes and boost energy independence.

The collaboration with ICT Mumbai, led by Prof. G.D. Yadav and his research team, focuses on scientific excellence, particularly in catalyst development and process optimisation. GBL's industry team has been instrumental in ensuring practical, scalable implementation.

This joint effort was recently honoured with the K.V. Mariwala Award for Effective Chemical Industry-Academia Partnership for 2024, recognizing scientific excellence, significant environmental impact, and clear pathways toward commercialisation.

The pilot project aims to convert 450 metric tons per day of biogenic CO2 into DME. GBL, an integrated biorefinery with global supply chain presence, sees this as an opportunity to lead in offering sustainable solutions, supported by India's push for clean energy and a circular economy.

ICT Mumbai, established in 1933, is a leading institute in chemical, biological, and energy sciences, with a legacy of sustainable technology development. Godavari Biorefineries Limited, a flagship company of the Somaiya Group, is a major producer of ethanol and bio-based chemicals, operating facilities in Maharashtra and Karnataka.

Godavari Biorefineries Limited, a company listed on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) under script symbol GODAVARIB and script code 544279 respectively, has formally issued an intimation regarding its upcoming earnings conference call. This call is scheduled to take place on Friday, November 14, 2025, commencing at 11:00 AM IST. The primary objective of this conference call is to discuss and analyse the company's financial and operational performance for the second quarter (Q2) and the first half (H1) of the fiscal year 2026.

The event will feature key members of the company's management, including Mr. Samir Somaiya, the Chairman & Managing Director, and Mr. Ashish Sinha, Assistant General Manager - Investor Relations & Finance. They are expected to provide insights into the company's performance, strategic initiatives, and outlook. Godavari Biorefineries Limited has also provided details for pre-registration and access numbers for the call, including primary dial-in options (+91 22 6280 1550, +91 22 7115 8378) and international toll-free numbers for regions like Hong Kong, Singapore, USA, and UK.

Crucially, the company has explicitly stated that no unpublished price-sensitive information (UPSI) is proposed to be shared during this meeting or call, assuring transparency and compliance with regulatory norms. The announcement itself was dated November 3, 2025, indicating timely disclosure of the conference call schedule. While specific financial figures for Q2 and H1 FY26 are not yet available in this announcement, the call serves as a platform for investors and analysts to gauge the company's performance trends and future prospects. This event is considered important for investors to understand the company's current standing and strategic direction.

Godavari Biorefineries Limited has announced that its Board of Directors will convene on November 11, 2025. The meeting's main purpose is to review and approve the company's unaudited financial results for both the second quarter (Q2) and the first half (H1) of the fiscal year ending September 30, 2025. These results will be presented on a standalone and consolidated basis.

Specific figures for revenue, profit, margins, or EPS are not yet available as this is an intimation prior to the results board meeting. The actual results will be disclosed after the November 11, 2025 meeting.

No management guidance or concall commentary is provided in this announcement.

No financial statements, balance sheet details, cash flow information, or key ratios are included in this intimation.

The most significant event is the scheduled Board Meeting for financial results approval on November 11, 2025. A critical related event is the confirmed closure of the trading window. This closure commenced on October 1, 2025, and will remain in effect for 48 hours following the declaration of the financial results. This is a standard regulatory procedure to prevent insider trading.

No outlook or future projections are discussed in this document.

Godavari Biorefineries Limited has formally announced the cessation of Mr. Sanjay Puri from his position as a Non-Executive Independent Director. The company confirmed via a filing dated October 29, 2025, that Mr. Puri's first term of appointment will conclude on October 29, 2025. Consequently, he will officially step down from his role as an Independent Director with effect from October 30, 2025. This announcement has been made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the relevant SEBI master circular dated November 11, 2024, concerning the appointment and cessation of directors. The disclosure specifies the reason for cessation as the completion of the director's first and final term, with no further details on his brief profile or relationships provided in this particular filing. This event represents a routine corporate governance update and does not include any information regarding financial results, company guidance, or operational performance.

Godavari Biorefineries Limited has announced the successful grant of its European patent application, titled 'COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH.' This patent originates from the company's dedicated Anti-Cancer Research Segment and protects novel chemical compounds specifically designed to inhibit unregulated cell proliferation. A key aspect highlighted is the compounds' ability to target cancer stem cells, which are crucial in tumor development and resistance.

The patent document provides detailed information on the chemical structures of these compounds, their synthesis processes, and their demonstrated biological activity. Early indications from research suggest these compounds possess strong therapeutic potential for various forms of cancer, including promising applications in treating breast and prostate cancer.

This grant represents a significant intellectual property milestone for Godavari Biorefineries, reinforcing its R&D capabilities and strategic positioning within the oncology market. It is a precursor to potential future product development and commercialization in the pharmaceutical or biopharmaceutical space, marking a substantial step in the company's long-term innovation strategy.

Godavari Biorefineries Limited has filed a mandatory compliance certificate for the quarter ended September 30, 2025, in accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This report, issued by MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent, confirms the proper handling of the dematerialisation process. The certificate assures regulatory bodies and investors that all securities submitted by depository participants for dematerialisation during the quarter were accurately processed. This includes the confirmation of acceptance or rejection of these securities to the respective depositories. A key aspect confirmed is that the securities contained within these certificates are indeed listed on the stock exchanges where Godavari Biorefineries Limited's shares are traded. Furthermore, the filing states that physical security certificates received for dematerialisation were duly verified, subsequently mutilated, and cancelled. Following this, the names of the depositories were registered as the official owners in the company's register of members within the stipulated timelines. This process is crucial for maintaining the integrity of shareholding records and ensuring seamless electronic trading of securities. The submission of this certificate is a routine regulatory requirement and does not indicate any specific financial performance, operational changes, or strategic developments for the company.

Godavari Biorefineries Limited has announced its intention to raise funds through public deposits and Non-Convertible Debenture (NCD) issuances. The company has published detailed advertisements and regulatory disclosures outlining these fundraising activities. Key financial data for the fiscal years 2022-23, 2023-24, and 2024-25 are provided, including net profit/loss figures which indicate a mixed performance with losses in FY24-25 and FY22-23, and a profit in FY23-24. The company plans to issue NCDs up to ₹8500.00 lakhs and has detailed information on its outstanding deposits. The disclosures include specific repayment terms, interest rates for various deposit tenures (1, 2, and 3 years), and conditions for secured and unsecured deposits. A past default amount of ₹7765.75 lakhs is also disclosed. Balance sheet details, including total assets, liabilities, and net worth for the last three fiscal years, are presented. The credit rating agency CRISIL is mentioned in relation to the NCDs. The overall communication aims to provide transparency to potential investors regarding the company's financial health and its capital raising strategies.

Godavari Biorefineries Limited has disclosed the voting results from its 70th Annual General Meeting (AGM), held on September 30, 2025. The disclosure, submitted on October 1, 2025, includes a consolidated Scrutinizer’s Report detailing the outcomes of shareholder voting on ten resolutions. The voting was conducted through remote e-voting facility provided from September 27 to September 29, 2025, and through electronic means during the AGM. A total of 94,407 shareholders were on record as of September 23, 2025. The meeting saw participation via video conferencing from 90 shareholders, comprising 16 from the promoter group and 74 public shareholders. Approximately 57.87% of the company's outstanding shares were polled during the voting process.

The resolutions considered included ordinary resolutions for the adoption of the audited financial statements for the fiscal year ended March 31, 2025, the appointment of a director retiring by rotation, the appointment of Tushar Shridharani and Associates LLP as Secretarial Auditor for five years, ratification of Cost Auditor remuneration, contribution to charitable funds, and special resolutions for the appointment of Mr. Nandan Dhanajay Mehta and Mr. Sean E. Reagan as Independent Directors, and the re-appointment of Mr. Hemant Luthra as an Independent Director for a second term.

All ten resolutions were passed by the shareholders with a significant majority. For most resolutions, the 'votes in favour' constituted over 99.99% of the votes polled. Even for resolutions like contribution to charitable funds and acceptance of deposits, which saw a small percentage of 'against' votes (12.09% and 10.04% respectively), the approval remained strong, with over 87% and 89% respectively voting in favour. This outcome indicates strong shareholder confidence in the company's management and corporate governance decisions. This filing does not contain any financial performance data or future guidance.

Godavari Biorefineries Limited, through its stock exchange filings on September 30, 2025, announced pivotal corporate governance decisions made at its 70th Annual General Meeting (AGM). The company informed about the shareholder approvals for director re-appointments and the appointment of a new secretarial auditor.

Specifically, Mr. Bhalachandra Bakshi (DIN: 03538688) and Mr. Suhas Godage (DIN: 09227610) were re-appointed as Directors, serving in roles that are subject to rotation as per company bylaws. Further strengthening the board's independent expertise, Mr. Nandan Dhanajay Mehta (DIN: 07134249) and Mr. Sean E. Reagan (DIN: 01490812) were appointed as Independent Directors. Their appointments are set for a term of five consecutive years, commencing from the date of approval. In addition, Mr. Hemant Luthra (DIN 00231420), an existing Independent Director, received approval for a second term, extending his service for another three consecutive years commencing October 30, 2025.

The AGM also ratified the appointment of Tushar Shridharani and Associates LLP (Firm Registration No. LLPIN - ACL-9350) as the company's Secretarial Auditor. This appointment is for a substantial term of five years, effective from April 1, 2025, through March 31, 2030. The appointment of the secretarial auditor had earlier received endorsement from the Board of Directors during their meeting on August 7, 2025, prior to its confirmation by the shareholders. The detailed profiles and requisite confirmations for all director and auditor appointments were furnished as per SEBI (LODR) Regulations, 2015, ensuring transparency and compliance. This announcement primarily signifies routine governance updates and board composition adjustments.

Godavari Biorefineries Limited announced the proceedings of its Seventieth Annual General Meeting (AGM), which took place on Tuesday, September 30, 2025, via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting commenced at 11:30 a.m. IST and concluded at 11:49 a.m. IST.

The primary agenda items, as per the notice dated August 7, 2025, included ordinary business such as the consideration and adoption of the Audited Financial Statements, including consolidated financial statements, for the Financial Year ended March 31, 2025, along with the reports of the Board of Directors and Auditors. Additionally, directors Mr. Bhalachandra Bakshi and Mr. Suhas Godage, who were retiring by rotation, were to be appointed/re-appointed.

Under special business, the members were set to vote on the appointment of Mr. Nandan Dhanajay Mehta and Mr. Sean E. Reagan as Independent Directors. The re-appointment of Mr. Hemant Luthra as an Independent Director for a second term of three years, effective October 30, 2025, was also on the agenda. Further resolutions concerned the appointment of the Secretarial Auditor, ratification of remuneration for the Cost Auditor, contributions to charitable funds, and acceptance of deposits.

The company confirmed that 90 members attended the meeting virtually. A quorum was present, and the meeting was conducted in compliance with applicable regulations. Remote e-voting facilities were available from September 27 to September 29, 2025, with an option for electronic voting during the meeting itself. The combined results of the voting will be intimated separately to the stock exchanges and uploaded on the company's and NSDL's websites. The disclosure provided a summary of the proceedings and the resolutions passed, but did not include specific financial performance details or future outlook commentary.

Godavari Biorefineries Limited has issued a formal intimation to the National Stock Exchange of India Limited and BSE Limited regarding the closure of its trading window. This strategic closure is implemented in accordance with the company’s internal 'Insider Trading Prohibition Code' and is in strict compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

The trading window for dealing in the securities of Godavari Biorefineries Limited will be officially closed from October 1, 2025. This restriction encompasses all Directors, Key Managerial Persons, Designated Persons within the company, as well as their immediate relatives and dependents. The closure is a standard preventative measure aimed at safeguarding against any potential insider trading activities.

The trading window is scheduled to remain shut until a duration of 48 hours has passed from the date of the declaration of the Unaudited Financial Results for the quarter and the half-year ended September 30, 2025. The specific date for the board meeting to approve these financial results has not yet been intimated and will be communicated in due course.

This announcement does not contain any specific financial performance data, quarterly or annual results, management guidance, or details regarding new orders, expansions, product launches, penalties, or other significant operational developments. It is purely a regulatory compliance notification to ensure transparency and fairness in the stock market. The company remains committed to adhering to all regulatory requirements and will provide further updates as and when financial results are declared.

Godavari Biorefineries Limited (GBL) has been honored with the ICC – K. V. Mariwala Award for Effective Chemical Industry–Academia Partnership at the 60th Annual ICC Awards, 2025, held on September 19, 2025. This prestigious award celebrates GBL's strong and transformative collaboration with the Institute of Chemical Technology (ICT), Mumbai. The partnership has led to the joint development of a breakthrough single-step catalytic conversion process for converting CO2 into Dimethyl Ether (DME). This technology efficiently utilizes biogenic CO2 generated from GBL's ethanol fermentation. DME is positioned as a clean fuel, a viable substitute for LPG and diesel, and a versatile chemical feedstock. The development was guided by Prof. G. D. Yadav and championed by Mr. Samir Somaiya, CMD, GBL. Mr. Somaiya commented that the award reflects GBL's longstanding commitment to sustainability, renewable chemistry, and the principles of a circular economy, highlighting that industry-academia partnerships are vital for India's competitiveness and addressing global sustainability challenges. GBL is recognized as a leader in renewable chemicals, green technologies, and biofuels, transforming agro-based raw materials into sustainable products and fostering talent through academic collaborations.

Godavari Biorefineries Limited (GBL) has been honored with the ICC - K. V. Mariwala Award for Effective Chemical Industry Academia Partnership. This award acknowledges the company's pioneering technology, jointly developed with the Institute of Chemical Technology (ICT), Mumbai, under the guidance of Prof. G. D. Yadav and the leadership of Mr. Samir Somaiya, CMD, GBL. The core innovation is a breakthrough single-step catalytic conversion process that transforms biogenic CO2, a byproduct of ethanol fermentation, into di-methyl ether (DME). This process is noted for its enhanced efficiency and cost-effectiveness compared to traditional methods. DME is a versatile clean fuel, suitable as a substitute for LPG and diesel, and also serves as a valuable feedstock for various chemical synthesis applications. Lab-scale validation and lifecycle assessments have confirmed the environmental and economic viability of this technology. It holds the potential for negative carbon intensity, positioning it as a globally replicable and scalable solution crucial for mitigating climate change by closing the carbon loop. This award underscores GBL's commitment to sustainable chemical processes and collaborative innovation.

Multiple Indian companies have issued notices related to routine corporate compliance and shareholder meetings.

Godavari Biorefineries Limited has announced its 70th Annual General Meeting (AGM) to be held on September 30, 2025. Shareholders will vote on financial statements for the fiscal year 2024-25, with e-voting facilities available. The notice, published on September 5, 2025, provides details on the e-voting period and procedures.

Abhinandan Enterprises Ltd. has called for its 41st Extraordinary General Meeting (EGM) on September 30, 2025, for shareholders to vote electronically on various matters. The company has also made its code of conduct available on its website and the MSEI website.

Veefin Technologies Ltd. will hold its 5th EGM on September 26, 2025, where shareholders will participate in e-voting. Financial statements and related documents will be made available to shareholders.

Chembond Technologies Ltd. has issued a notice regarding unclaimed dividends, announcing a moratorium period and providing detailed instructions for shareholders to claim their outstanding dividends. Shareholders must submit claims with necessary documentation within 100 days, or by November 2025, to avoid their claims being forfeited.

Shree Guru Deva Enterprises Pvt. Ltd. had announced its 36th EGM on November 4, 2020, which is an older, routine compliance event.

Godavari Biorefineries Limited has released its 70th Annual Report for the Financial Year 2024-25, detailing its performance and strategic direction. The company reported a consolidated revenue growth of 11% YoY to ₹1,870.25 Cr, driven by its bio-based chemicals and distillery segments. However, consolidated EBITDA saw a decline of approximately 19% YoY to ₹120.31 Cr. The company incurred a net loss, both on a standalone and consolidated basis, with a one-time deferred tax expense of ₹2,449.45 Lakhs impacting the results. Basic and Diluted EPS stood at -(₹5.92) on a standalone basis. Post-IPO, the company significantly improved its financial health, reducing its consolidated debt-to-equity ratio to 0.46 from 0.71 in the previous year, funded by the ₹554 Cr IPO proceeds primarily used for debt repayment. Key strategic priorities include scaling up bio-based specialty chemicals, increasing ethanol capacity utilization through feedstock diversification like maize, enhancing farmer co-creation, and maintaining sustainability as a core driver. The company is also advancing its R&D in drug discovery for cancer treatment and plans to commission a maize-based ethanol facility by end-2025. The Jivana brand showed strong growth, crossing ₹100 Cr in turnover.

Godavari Biorefineries Limited has formally announced its 70th Annual General Meeting (AGM) will be held on Tuesday, September 30, 2025, commencing at 11:30 AM IST. The meeting will be conducted entirely through Video Conferencing (VC) / Other Audio Visual Means (OAVM), adhering to recent regulatory allowances. The primary agenda item is the consideration and adoption of the audited financial statements, including consolidated figures, for the financial year ended March 31, 2025, along with the reports from the Board of Directors and Auditors.

Key governance matters on the agenda include the re-appointment of directors retiring by rotation: Mr. Bhalachandra Bakshi and Mr. Suhas Godage. Furthermore, the company proposes to appoint two new Independent Directors: Mr. Nandan Dhananjay Mehta and Mr. Sean E. Reagan, both for a term of five consecutive years. A special resolution is also sought for the re-appointment of Mr. Hemant Luthra as an Independent Director for a second term of three years, commencing October 30, 2025, notably after he has attained the age of 75 years.

Other significant proposals include the appointment of Tushar Shridharani and Associates LLP as Secretarial Auditors for a five-year term (April 1, 2025, to March 31, 2030). The remuneration payable to the Cost Auditor for the financial year ending March 31, 2026, will be ratified. Shareholders will also vote on a proposal to contribute up to Rs. 2.25 Crore to charitable and other funds, and to accept deposits from the public and members. The company has provided detailed instructions for shareholders on remote e-voting, which will be open from September 27 to September 29, 2025, and for attending the virtual AGM, with September 23, 2025, as the record date for voting rights.

Godavari Biorefineries Limited is holding its 70th Annual General Meeting (AGM) on Tuesday, September 30, 2025, at 11:30 AM IST. The meeting will be conducted virtually through Video Conferencing (VC) or Other Audio Visual Means (OAVM). As per SEBI Listing Regulations, the company is informing shareholders whose email addresses are not registered by dispatching a letter containing a web-link to access the complete Annual Report for the Financial Year 2024-25 on its website. The direct link to the Annual Report is provided as: https://godavaribiorefineries.com/sites/default/files/Godavari_Biorefineries_Ltd_Annual_Report_2024-25.pdf. Additionally, the company is reminding shareholders holding physical securities to update their Know Your Customer (KYC) details as per SEBI Master Circular SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024. This includes updating PAN, address with PIN code, mobile number, bank account details, specimen signature, and nomination choice. Security holders with incomplete KYC details in their folios may only receive payments like dividends or interest through electronic modes from April 1, 2024. Shareholders with queries can contact investors@somaiya.com or 022-61702100, and are encouraged to update their email addresses to receive future communications efficiently and support green initiatives.

This compilation includes notices from several Indian companies regarding their upcoming Annual General Meetings (AGMs) scheduled for September 2025. Companies such as Godavari Biorefineries Limited, Durlax Top Surfaces Limited, Enser Technologies Limited, Hi-Class Services Limited, and RRPSemiconductors Limited have informed shareholders about the procedures for these AGMs, which will be conducted via Video Conference (VC) or Other Permitted Audiovisual Means (OOVM). These notifications outline the availability and process for e-voting and specify the book closure periods, ensuring compliance with SEBI LODR Regulations. Shareholders are guided on how to participate remotely and cast their votes. In a distinct development, Adani Housing Finance Limited has been issued a property auction notice stemming from a loan default, indicating a significant debt recovery action that could involve asset seizure.

Godavari Biorefineries Limited has formally announced its schedule to interact with analysts and institutional investors on Monday, September 15, 2025. The event is the 'Avendus Spark-Exclusive Small Cap Investor Conference', which will take place physically at the Avendus Office in Platina, Bandra Kurla Complex, Mumbai. Company officials will participate in both one-on-one and group meeting formats. In compliance with SEBI regulations, the company has clarified that all discussions during these meetings will be based solely on publicly available information, and no unpublished price sensitive information (UPSI) will be shared or discussed.

Godavari Biorefineries Limited conducted an investor/analyst conference call on August 11, 2025, to discuss its financial performance for Q1 FY26. The company reported a revenue from operations of ₹533.2 crores, a year-on-year increase from ₹522.5 crores in Q1 FY25, marking a steady growth. Profitability saw a significant turnaround, with EBITDA reaching ₹6.5 crores, a substantial improvement from a loss in the prior year's quarter, attributed to cost optimization, growth in the bio-based chemical segment, ethanol blending program restoration, and lower interest costs. Gross margin expanded by 512 basis points YoY to 19%. Interest costs reduced by 22% YoY to ₹15 crores due to debt reduction efforts.

The management highlighted a strategic shift towards bio-based specialty chemicals and renewable energy. The bio-based chemical segment's EBITDA increased by a robust 43% YoY. The company is advancing its ethanol business with a new 200 KLPD fungible grain/maize distillery, on track for commissioning by the end of CY2025, expected to contribute EBITDA from Q4 FY26. This move diversifies feedstock and aligns with government initiatives promoting ethanol blending, with discussions of increasing the blend to 27%.

In drug discovery, a novel anti-cancer molecule received European patent validation and concluded safety trials without dose-limiting toxicity. Another compound secured a Chinese patent. Commercialization of these molecules is estimated to be 2-3 years away, contingent on efficacy trials and regulatory approvals.

Looking ahead, the company aims to increase the contribution from ethanol and bio-based specialty chemicals to revenue, targeting 40-45% each in the long term, while sugar and co-generation remain stable. A ₹325 crore capex plan is envisaged for the next phase of growth, with 70% allocated to bio-based specialty chemicals and 30% to ethanol capacity. The company anticipates a 3x increase in EBITDA from FY25 to FY29, driven by these segments, with major impacts expected from FY27 onwards. The effective tax rate is expected to be 25%. The Catalyxx partnership for bio-butanol is in the engineering stage, targeting plant startup in H2 next year.

Godavari Biorefineries Limited announced on August 15, 2025, that it has been recommended for the prestigious ICC – K. V. MARIWALA AWARD FOR EFFECTIVE CHEMICAL INDUSTRY - ACADEMIA PARTNERSHIP for the year 2024. This recognition is a testament to the company's strong collaboration with the Institute of Chemical Technology Mumbai. The International Chamber of Commerce (ICC) Awards Selection Committee evaluated nominations and selected Godavari Biorefineries for its significant contributions in fostering effective partnerships between the chemical industry and academia. The award ceremony, which will honour outstanding achievements in various facets of the chemical industry for 2024, is scheduled to take place on Friday, September 19, 2025. This award highlights the company's commitment to innovation and academic engagement within the chemical sector. No financial data, performance metrics, guidance, or other specific operational details were provided in this announcement.

Godavari Biorefineries Limited has informed exchanges about an upcoming interaction with analysts and institutional investors. The meetings are scheduled for August 20, 2025, and will take place physically as part of the Equirus Annual India Conference '25. The company officials will engage in both one-on-one and group meeting formats. A key highlight of the disclosure is the explicit statement that discussions will be strictly based on publicly available information. The company has confirmed that no unpublished price-sensitive information is proposed to be shared or discussed during these interactions. This event falls under the purview of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring compliance with disclosure norms.

Godavari Biorefineries Limited has informed the stock exchanges (NSE and BSE) about the availability of the audio recording for its Q1 FY26 earnings conference call. The company has uploaded the recording on its official website, in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This announcement allows investors and stakeholders to access management's discussions and insights pertaining to the company's performance during the first quarter of the financial year 2025-26.

This disclosure serves as a procedural update, providing a direct link for accessing the playback of the conference call, which typically covers financial results, operational performance, segment-wise data, management commentary on outlook, growth drivers, risks, and strategic initiatives. However, the specific financial figures, performance metrics, or management guidance were not detailed in this particular notification.

Godavari Biorefineries Limited released its Q1 FY26 investor presentation, highlighting mixed financial performance. Total Income increased by 2% YoY to Rs. 534.0 Cr. The company achieved a positive EBITDA of Rs. 6.5 Cr (EBITDA margin 1.2%), a significant turnaround from a loss of Rs. (9.5) Cr (margin -1.8%) in Q1 FY25. This improvement was driven by the ethanol segment's recovery, specialty chemicals focus, and a 21.9% YoY reduction in finance costs to Rs. 15.3 Cr, following debt repayment. Profit After Tax (PAT) remained a loss at Rs. (16.0) Cr (margin -3.0%), though it narrowed from a loss of Rs. (26.1) Cr in the prior year. Segment-wise, Ethanol revenue surged 51% YoY to Rs. 205.4 Cr, with EBITDA growing by 13.9% YoY to Rs. 13.1 Cr. Bio-based Chemicals revenue saw a slight decline of 3% YoY to Rs. 141.2 Cr, but EBITDA improved by 43.7% YoY to Rs. 12.5 Cr, reflecting a strategic shift towards specialty chemicals. The Sugar & Co-generation segment revenue dropped 24% YoY to Rs. 177.5 Cr, with a reduced EBITDA loss. The company is expanding its 200 KLPD grain/maize distillery, expected to add 60 Mn liters of ethanol capacity by end-CY25. The outlook targets 3X EBITDA growth by FY29, with specific growth drivers in Bio-based Chemicals (targeting 2.5x revenue, 15%+ EBITDA margin) and Ethanol (targeting 2.5x revenue, 10%+ EBITDA margin). Significant R&D milestones include European patent validation for an anti-cancer molecule.

CARE Ratings Limited has issued its Monitoring Agency Report for Godavari Biorefineries Limited for the quarter ended June 30, 2025. The report confirms that the utilization of the company's Initial Public Offering (IPO) proceeds, aggregating ₹325 crore, has been in line with the objects disclosed in the Offer Document.

Regarding financial performance, the report mentions that Godavari Biorefineries incurred a net loss of ₹23 crore in the financial year 2024-25 (FY25), a shift from a net profit of ₹12 crore in FY24. This loss includes a one-time notional deferred tax liability of ₹24 crore recognized as per IND AS, attributed to changes in Income Tax laws impacting indexation benefits for corporates. No asset sales occurred during FY25.

Analysis of IPO proceeds utilization reveals that out of the total ₹325 crore raised, ₹322.80 crore was utilized as of June 30, 2025, leaving ₹2.20 crore unutilized, held in bank accounts.

Key utilization categories:

• Issue Expense: Original ₹21.39 crore, revised to ₹19.93 crore. ₹17.79 crore was utilized, with ₹2.14 crore remaining unutilized. A significant development was the board-approved reclassification of ₹1.46 crore from surplus issue expenses to General Corporate Purposes (GCP), supported by a legal opinion deeming board approval sufficient for this modification, though SEBI regulations might imply a need for shareholder approval for material deviations. The board also permitted the transfer of an additional surplus of up to ₹2.25 crore from issue expenses to GCP as needed.
• Repayment/Prepayment of borrowings: ₹240.00 crore was fully utilized as per the original and revised plan.
• General Corporate Purposes (GCP): Original ₹63.61 crore, revised to ₹65.07 crore. ₹65.01 crore was utilized, with ₹0.06 crore remaining unutilized. This category benefited from the ₹1.46 crore reclassification.

The report states no delay in the implementation of the objects for repayment of borrowings and GCP, although the timeline for issue expenses utilization was not specified in the offer document. Overall, the report indicates adherence to IPO fund deployment plans with minor board-approved adjustments.

Godavari Biorefineries Limited has filed an intimation with the stock exchanges regarding its participation in an Analyst/Institutional Investor Meet. The company's officials are scheduled to interact with analysts and investors on August 14, 2025. This engagement is part of the 'Emkay Confluence - India Ascending: The Next Leap' event, where meetings will be conducted in a physical format, comprising both one-on-one and group sessions. A critical point highlighted in the disclosure is that the discussions will solely be based on information that is already in the public domain. The company explicitly stated that no unpublished price-sensitive information (UPSI) will be shared or discussed during these interactions. This announcement does not contain any financial results, performance metrics, new guidance, or specific business updates beyond the scheduling of the meeting itself.

Godavari Biorefineries Limited announced its unaudited financial results for the quarter ended June 30, 2025 (Q1 FY25) on August 8, 2025. The results were published in Financial Express and Mumbai Lakshdeep.

Consolidated Financial Highlights:

• Revenue from Operations: ₹1,89,381.05 Lakhs. This represents a substantial year-on-year (YoY) growth of 535% from ₹29,611.32 Lakhs in Q1 FY24. However, quarter-on-quarter (QoQ), revenue decreased by 42.30% from ₹3,28,068.17 Lakhs in Q4 FY25.
• Profit After Tax (PAT): ₹3,269.23 Lakhs. YoY PAT grew by 35% compared to ₹2,421.44 Lakhs in Q1 FY24. On a QoQ basis, PAT saw a sharp decline of 69.87% from ₹10,851.06 Lakhs in Q4 FY25.
• Profit Before Tax (PBT): ₹4,113.88 Lakhs, up 42% YoY from ₹2,893.29 Lakhs in Q1 FY24.
• Basic EPS: ₹6.46, a YoY increase of approximately 34%.
• Diluted EPS: ₹21.56, a YoY increase of approximately 21%.

Standalone Financial Highlights:

• Revenue from Operations: ₹76.43 Lakhs, a YoY decrease of 26% from ₹103.71 Lakhs in Q1 FY24.
• Profit After Tax (PAT): The company reported a loss of ₹142.74 Lakhs, which is an improvement from the loss of ₹202.34 Lakhs recorded in Q1 FY24.

The company confirmed compliance with SEBI regulations for the dissemination of financial results.

Godavari Biorefineries Limited announced its financial results for the quarter ended June 30, 2025 (Q1 FY26), showcasing a resilient performance amidst business seasonality.

Quarterly Performance:

• Total Income: The company reported a consolidated total income of ₹534.0 Cr, a 1.65% increase year-on-year (YoY) from ₹525.3 Cr in Q1 FY25, but a sequential decline of 9.31% from ₹588.8 Cr in Q4 FY25. Full FY25 income was ₹1,886.9 Cr.
• EBITDA: EBITDA turned positive at ₹6.5 Cr compared to a loss of ₹9.5 Cr in Q1 FY25, representing a significant YoY improvement of 168.42%. However, sequentially, EBITDA dropped by 94.66% from ₹121.7 Cr in Q4 FY25. The EBITDA margin stood at 1.2%, up from -1.8% YoY but down from 20.7% QoQ. The company noted that EBITDA includes other income.
• PAT: Profit After Tax (PAT), excluding a one-time deferred tax impact, was a loss of ₹16.0 Cr, an improvement from a loss of ₹26.1 Cr in Q1 FY25 (YoY improvement of 38.69%). Sequentially, PAT fell sharply from a profit of ₹71.9 Cr in Q4 FY25.
• Ethanol Production: The company significantly ramped up ethanol production, with volumes at 25,082 KL in Q1 FY26, a 192.4% YoY increase from 8,658 KL in Q1 FY25. This was supported by the restoration of the Ethanol Blending Program from Juice/Syrup, enabling higher production from B-heavy molasses.

Management Commentary & Outlook:
Shri Samir Somaiya, CMD, emphasized the company's resilience and progress. He highlighted the strong 43% YoY EBITDA growth in the Bio-Based Chemicals segment. The company is enhancing its multi-feedstock ethanol capabilities and investing in R&D. A key development is significant progress in drug discovery efforts, with patents validated in Spain, the UK, and for multiple EU member states for a novel anti-cancer molecule. Additionally, a patent for another anti-cancer molecule was granted by China. The company remains focused on strengthening its bio-based chemicals segment through debottlenecking and developing specialty chemicals, confident in creating sustainable value.

Key Events:
The company announced the validation of a European patent for a novel anti-cancer molecule and the grant of a patent by the China National Intellectual Property Administration (CNIPA) for another anti-cancer molecule, indicating progress in its R&D initiatives.

Financial Deep Dive (limited data):
Key ratios like ROE/ROCE, debt-to-equity, interest cover, and cash flow metrics were not detailed in this release. Balance sheet data was also not provided.

The provided text consists of biographical annexures detailing the professional experience of Nandan Mehta, associated with Tata Consultancy Services (TCS), and Sean E. Reagan, a finance executive formerly with Dow Chemical and currently with Garrett Motion. Crucially, this content does not contain any financial results, performance metrics, company guidance, outlooks, or specific market-moving news relevant to the Indian stock market.

Nandan Mehta's profile outlines his responsibilities in corporate affairs for the Europe, Middle East, and Africa (EMEA) region for TCS, and his prior role as head of finance for TCS's cloud computing division, iON. Sean E. Reagan's extensive background includes significant leadership roles in finance and tax at major multinational corporations. His tenure at Dow Chemical involved roles such as Chief Financial Officer for South Asia, where he managed substantial revenue growth (from ~$180 million to ~$1 billion), oversaw finance operations across multiple locations, and partnered in establishing Centers of Excellence in India. He also has broad experience in global tax planning, legislative advocacy, and leading complex M&A transactions, including the DowDupont merger and structuring joint ventures. At Garrett Motion, he serves as Vice President Global Tax & Corporate Finance Oversight, managing global tax functions, financial restructuring (including Chapter 11), and transformations within India's finance operations.

While the profiles mention companies that operate in or have significant connections to India (TCS, Dow's South Asia operations, Garrett's India Finance transformation), the information presented is purely biographical and professional. It does not include any financial data such as revenue, EBITDA, PAT, margins, EPS, cash flow, debt, or ratios, nor does it discuss future outlooks, growth drivers, risks, specific orders, expansions, product launches, or regulatory updates that would directly impact an Indian retail investor's decision-making process. Consequently, most fields in the JSON output will be null.

NA